

1 **Title: Single-cell characterisation of mononuclear phagocytes in the human intestinal**  
2 **mucosa**

3  
4 **Authors:** Thomas M. Fenton<sup>1,2,†\*</sup>, Line Wulff<sup>1,†</sup>, Gareth-Rhys Jones<sup>2</sup>, Julien Vandamme<sup>1</sup>, Peter  
5 B. Jørgensen<sup>1</sup>, Calum C. Bain<sup>2</sup>, Julie Lee<sup>3</sup>, Jose MG. Izarzugaza<sup>4</sup>, Kirstine G. Belling<sup>5</sup>, Gwo-  
6 Tzer Ho<sup>2</sup>, Ole H. Nielsen<sup>6</sup>, Lene B. Riis<sup>7</sup>, Tune H. Pers<sup>8</sup>, Henrik L. Jakobsen<sup>9</sup>, Allan M. Mowat<sup>10</sup>,  
7 Søren Brunak<sup>5</sup>, William W. Agace<sup>1,11,\*</sup>

8  
9 **Affiliations:**

10 <sup>1</sup>Mucosal Immunology group, Department of Health Technology, Technical University of  
11 Denmark, Kemitovet, 2800 Kgs. Lyngby, Denmark

12 <sup>2</sup>University of Edinburgh Centre for Inflammation Research, Queens Medical Research institute,  
13 Edinburgh, EH16 4TJ, UK

14 <sup>3</sup>Novo Nordisk Foundation Centre for Stem Cell Biology, DanStem, University of Copenhagen,  
15 2200 Copenhagen N, Denmark

16 <sup>4</sup>Center for Biological Sequence Analysis, Technical University of Denmark, 2800 Lyngby,  
17 Denmark

18 <sup>5</sup>Translational Disease Systems Biology, Novo Nordisk Foundation Centre for Protein Research,  
19 Faculty of Health and Medical Sciences, University of Copenhagen, 2200 Copenhagen,  
20 Denmark

21 <sup>6</sup>Department of Gastroenterology, Medical Section, Herlev Hospital, University of Copenhagen,  
22 2730 Herlev, Denmark.

23 <sup>7</sup>Department of Pathology, Herlev Hospital, University of Copenhagen, 2730 Herlev, Denmark

24 <sup>8</sup>Novo Nordisk Foundation Centre for Basic Metabolic Research, University of Copenhagen,  
25 2200 Copenhagen N, Denmark

26 <sup>9</sup>Department of Gastroenterology, Surgical Section, Herlev Hospital, University of Copenhagen,  
27 2730 Herlev, Denmark.

28 <sup>10</sup>Institute of Infection, Immunity and Inflammation, College of Medicine, Veterinary Medicine  
29 and Life Sciences, University of Glasgow, Glasgow, UK

30 <sup>11</sup>Immunology Section, Lund University, BMC D14, 221-84 Lund, Sweden

31

32 †These authors contributed equally to this work

33 \*Corresponding authors: [thomas.m.fenton@gmail.com](mailto:thomas.m.fenton@gmail.com), [wiaq@dtu.dk](mailto:wiaq@dtu.dk)

34

35

36 **Abstract**

37 Subsets of mononuclear phagocytes, including macrophages and classical dendritic cells (cDC),  
38 are highly heterogeneous in peripheral tissues such as the intestine, with each subset playing  
39 distinct roles in immune responses. Understanding this complexity at the cellular level has proven  
40 difficult due to the expression of overlapping phenotypic markers and the inability to isolate  
41 leukocytes of the mucosal lamina propria (LP) effector site, without contamination by the isolated  
42 lymphoid follicles (ILFs), which are embedded in the mucosa and which are responsible for the  
43 induction of immunity. Here we exploit our novel method for separating lamina propria from  
44 isolated lymphoid follicles to carry out single-cell RNA-seq, CITE-seq and flow cytometry analysis  
45 of MNPs in the human small intestinal and colonic LP, without contamination by lymphoid follicles.  
46 As well as classical monocytes, non-classical monocytes, mature macrophages, cDC1 and  
47 CD103<sup>+</sup> cDC2, we find that a CD1c<sup>+</sup> CD103<sup>-</sup> cDC subset, which shares features of both cDC2  
48 and monocytes, is similar to the cDC3 that have recently been described in human peripheral  
49 blood. As well as differing between the steady-state small intestine and colon, the proportions of  
50 the different MNP subsets change during different stages of inflammatory bowel disease (IBD)  
51 inflammation. Putative cDC precursors (pre-cDC) were also present in the intestine, and trajectory  
52 analysis revealed clear developmental relationships between these and subsets of mature cDC,  
53 as well as between tissue monocytes and macrophages. By providing novel insights into the  
54 heterogeneity and development of intestinal MNP, our findings should help develop targeted  
55 approaches for modulating intestinal immune responses.

56

57

## 58 **Introduction**

59

60 The mononuclear phagocyte (MNP) family consists of classical dendritic cells (cDC), classical  
61 monocytes, non-classical monocytes, and macrophages, each of which play specific roles in the  
62 induction and function of immune responses, tissue homeostasis and inflammation (Arroyo  
63 Portilla et al., 2021; Caër and Wick, 2020; Joeris et al., 2017). Whereas cDC are the main cells  
64 involved in the induction and shaping of adaptive immune responses and tolerance (Cabeza-  
65 Cabrerizo et al., 2021), macrophages are primarily involved in maintaining tissue homeostasis,  
66 and in promoting inflammation in response to infection or tissue damage (Bain and Schridde,  
67 2018; Na et al., 2019). Thus, characterising these populations and understanding their functions  
68 under different conditions will be important for improving the treatment of disease and for  
69 developing preventative strategies, such as vaccines. However, this has proved difficult due to  
70 the expression of overlapping phenotypic markers and due to the heterogeneity within each  
71 subset, which is becoming increasingly evident (Brown et al., 2019; Dutertre et al., 2019; Guilliams  
72 et al., 2016; Villar and Segura, 2020). This is particularly so in non-lymphoid tissues such as the  
73 intestine, where local factors imprint unique adaptations and functions, meaning that each tissue  
74 has to be explored independently and at the single-cell level (Blériot et al., 2020).

75

76 All MNP subsets are abundant in the human intestine, where they are thought to play  
77 important roles in disorders such as the inflammatory bowel diseases ulcerative colitis and  
78 Crohn's disease (Bernardo et al., 2018; Viola and Boeckxstaens, 2020). However, much of what  
79 is known about intestinal MNPs comes from work in mice and there are very few direct  
80 comparisons of these cells in the small and large intestine, which represent anatomical  
81 compartments with distinct functions and properties (Mowat and Agace, 2014). Furthermore,  
82 although recent work has examined human intestinal leukocytes at the single-cell level (Chapuy  
83 et al., 2019; Martin et al., 2019), these studies did not discriminate between cells in the mucosal

84 lamina propria (LP) and those in the secondary lymphoid organs of the gut-associated lymphoid  
85 tissues (GALT), which include the isolated lymphoid follicles (ILFs) which are embedded in the  
86 LP (Mörbe et al., 2021; Senda et al., 2019; Spencer et al., 2019). As these compartments have  
87 distinct roles in local immunity - with the GALT being responsible for the initiation of antigen-  
88 specific B and T cell responses, while the effector responses take place in the LP and epithelium  
89 (Barone et al., 2011; Boursier et al., 2005; Masahata et al., 2014) - it is critical to assess their  
90 cellular components independently. Recently, we developed a novel technique which allows ILFs  
91 of the GALT and the surrounding LP to be isolated separately from human intestinal tissue  
92 (Jørgensen et al., 2021). By combining this method with CyTOF, flow cytometry, and IgA-seq, we  
93 previously generated an atlas of effector lymphocytes in the LP of the small intestine and colon,  
94 and showed that these compartments contain very different populations of T and B cells (Fenton  
95 et al., 2020). Here, we have applied the same approaches to analyse the heterogeneity of MNP  
96 that are derived unequivocally from the LP of healthy and inflamed human small intestine and  
97 colon. As well as separate clusters of mature macrophages, we show that mucosal cDC can be  
98 divided into three distinct subsets and, for the first time, describe the presence of putative cDC  
99 precursors (pre-cDC) in the human intestine. Trajectory analysis revealed clear developmental  
100 relationships between tissue monocytes and macrophages, and between pre-cDC and mature  
101 DC. By providing novel insights into the heterogeneity and development of intestinal MNP, our  
102 findings should help target approaches for modulating intestinal immune responses.

103

## 104 Results

### 105 106 Single-cell sequencing of MNP subsets from the human intestinal mucosa

107 To characterise MNP diversity within the human intestinal LP, surgical samples of ileum and colon  
108 from uninvolved areas of colorectal cancer patients were processed to remove contaminating  
109 GALT and submucosa (SM), as we recently described (Fenton et al., 2020; Jørgensen et al.,  
110 2021). Following LP digestion, single-cell RNA sequencing (scRNA-seq) was performed on flow  
111 cytometry sorted  $CD45^+CD3^+CD19^-HLADR^{int/+}$  cells from ileal and colonic LP cell suspensions,  
112 using the 10x Chromium system (**Fig. 1A**). Sequences were obtained from a total of six colonic  
113 LP and four paired ileal LP samples (**Table S1**). Distinct clusters of  $CD3E^+$  T cells,  $CD79A^+$  B  
114 cells,  $VWF^+$  endothelia,  $MS4A2^+$  mast cells,  $COL3A1^+$  stroma, and  $NRXN1^+$  glia were identified  
115 and excluded from further analysis (**Fig. S1A**). Expression of *HLA-DQA1* (MHCII) identified  
116 one ‘supercluster’ and two peripheral clusters (**Fig. S1B**), which were computationally isolated  
117 and re-clustered. These 28,758 MHCII<sup>+</sup> cells included distinct clusters of  $IL3RA^+$  pDC,  $CLEC9A^+$   
118 cDC1, and  $FCGR3A^+$  non-classical monocytes (**Fig. S1C and 1B**), and a supercluster containing  
119 cells expressing either the cDC2-associated marker *CD1C*, the monocyte/macrophage  
120 (Mono/Mac) -associated marker *CD14*, or both *CD1C* and *CD14* (**Fig. 1C**). Flow cytometry  
121 analysis of colon LP  $CD45^+$   $HLA-DR^+$  lineage<sup>-</sup> cells confirmed the presence of CD1c and CD14  
122 single positive cells, as well as a cells expressing variable levels of both CD1c and CD14 (**Fig.**  
123 **1D**).

124 To further characterise subsets within this MNP supercluster, these cells were again re-  
125 clustered, at high resolution, and were analysed for expression of a curated panel of monocyte,  
126 macrophage, and cDC2/3 signature genes (**Fig. 1E**). Three broad populations could be identified,  
127 with population 1 (clusters X1-6) expressing the classical monocyte transcription factor *ZBTB16*  
128 (Cytlak et al., 2020), population 2 (clusters X7-X20) expressing the macrophage-associated  
129 genes *SEPP1*, *MERTK* and *MAF*, and population 3 (clusters X21-X35) expressing the cDC2/3-

130 associated genes *AP1S3*, *FLT3* and *SEPT6* (Guilliams et al., 2016; Miller et al., 2012), (**Fig. 1E**).  
131 The monocyte and macrophage clusters expressed Mono/Mac-specific TFs *ZBTB16*, *MAFB*, and  
132 *MAF*, and other TFs involved in tissue-resident macrophage development such as *ID3* (T'Jonck  
133 et al., 2018). These were mutually exclusively expressed with the TF *IRF4*, which is associated  
134 with cDC2 (Guilliams et al., 2016; Yin et al., 2017) (**Fig. 1E**). Some genes previously used as  
135 signature markers to discriminate cDC2/3 from monocytes in blood, such as *FCER1A* and  
136 *CLEC10A* (Dutertre et al., 2019), were broadly expressed amongst most clusters, and thus were  
137 not useful in segregating these populations in the human gut (**Fig. 1E**).

138  
139 As a result of this analysis, all clusters except X36-39 could be identified as putative  
140 cDC2/3 or as Mono/Mac (**Fig. 1F**). These remaining clusters expressed both cDC2-associated  
141 genes including, *FLT3* and *IRF4*, and Mono/Mac-associated genes, including *CD14* and *C5AR1*  
142 (*CD88*) (**Fig. 1E**). Since cDC3 co-express such markers (Bourdely et al., 2020; Cytlak et al., 2020;  
143 Dutertre et al., 2019; See et al., 2017; Villani et al., 2017; Yin et al., 2017) we classified clusters  
144 X36-39 as cDC3, of which cluster X38 also expressed a strong IFN-response signature (e.g.  
145 *CXCL9*, *CXCL10*, and *WARS*) (**Fig. 1E**).

146  
147 To assess the accuracy in designating these clusters as monocytes, macrophages and  
148 DC2/3, pseudo-bulk PCA analysis of the clusters was performed using three datasets of MNP  
149 gene signatures taken from different studies using blood cDC2, classical monocytes, and *in vitro*  
150 monocyte-derived macrophages (Carpentier et al., 2016; Goudot et al., 2017) which were  
151 previously collated (Tang-Huau et al., 2018). Consistent with our first supervised analytical  
152 approach, these clusters again separated into three groups, with PC1 driving separation of  
153 cDC2/3 and PC2 separating monocytes from macrophages (**Fig. 1G**). In summary, while showing  
154 a high degree of transcriptional overlap, by combining high resolution clustering and gene

155 expression analysis of published data sets we were able to separate intestinal LP MNP into  
156 monocytes, macrophages, cDC1, pDC and cDC2/3.

157

### 158 **Human intestinal CD1c<sup>+</sup> MNP include both cDC2 and cDC3**

159 To further explore diversity within the cDC2/3 populations, clusters X21-39 (Fig. 1F) were  
160 computationally isolated and re-clustered, and six distinct clusters were identified (**Fig. 2A**).

161 Clusters Y5 and Y6 expressed Mono/Mac-associated genes, including *S100A9*, *CD163*, *FCN1*  
162 and *FCGRT*, and showed lower expression of *IRF4* compared with the other clusters, indicative  
163 of cDC3 (Bourdely et al., 2020; Girard et al., 2020) (**Fig. 2B and C**). In contrast, cluster Y2 lacked

164 expression of Mono/Mac-associated genes, and expressed genes previously associated with  
165 cDC2, including *CD207*(Lim et al., 2020; De Monte et al., 2016), *NET1*(Girard et al., 2020), and

166 *IRF4*(Dutertre et al., 2019)(**Fig. 2B and C**). Y2 also highly expressed other signature genes  
167 enriched in human blood cDC2 vs cDC3 (Bourdely et al., 2020), including *ZEB1*, *ADAM19* and  
168 *LAD1* (**Fig S2A**). Interestingly, cluster Y5 contained the CXCL9<sup>+</sup> CXCL10<sup>+</sup> cells identified in Fig.

169 1 as potentially responding to IFN (**Fig. 2D and S2B**). Thus, cluster Y2 appeared to contain bona

170 fide cDC2, while Y5 and Y6 contained cells resembling cDC3. In order to investigate possible  
171 functional differences between the cDC2 and cDC3, we assessed their differential expression of

172 immunologically relevant genes which could have been missed by statistical tests of differential  
173 expression. cDC2 and cDC3 showed differential expression of multiple genes with immune

174 functions, including Fc receptors and cytokines, as well as transcription factors, suggesting  
175 possible functional differences between the cells (**Fig. 2D**).

176

177 Cluster Y3 showed mixed expression of cDC2 and cDC3 signatures (**Fig. 2C, Fig S2A**), but  
178 expressed genes associated with stimulus-response, including *FOS* and *JUN* (**Fig. 2B and S2C**).

179 This cluster contains a heterogeneous mix of cDC2 and cDC3 cells which were clustered together

180 due to shared transcriptional states rather than lineage identities. Finally, Clusters Y1 and Y4  
181 expressed low levels of MHCII genes and high levels of cell-cycle associated genes, including  
182 *KIAA0101* and *MKI67* (**Fig. 2C and S2C**), and thus resembled precursors and will be further  
183 discussed below.

184

### 185 **Human CD1c<sup>+</sup>CD14<sup>low</sup> intestinal cDC3 can be distinguished from cDC2 by low levels of** 186 **CD103 and CD207**

187 To identify surface markers that have the potential to distinguish intestinal cDC2 from cDC3, a  
188 Legendscreen antibody panel was used to screen for surface antigens which showed a bimodal  
189 expression pattern on colonic CD1c<sup>+</sup>CD14<sup>low</sup> MNP. Of 288 surface markers, only CD1a, CD11a,  
190 CD103, CD206, and CD207 showed bimodal expression within CD1c<sup>+</sup>CD14<sup>-</sup> MNP (**Fig. S2D**). To  
191 map expression of these surface markers to the cDC2/3 scRNA-seq clusters, these antibodies  
192 were included within a CITE-seq panel to stain intestinal LP cell suspensions (3 colon LP samples  
193 and 1 matched ileal LP sample). The main cDC2 cluster, Y2, expressed moderate-to-high levels  
194 of CD103, high levels of CD207, and relatively low levels of CD11a (**Fig. 2E**). In contrast, the  
195 cDC3 clusters Y5 and Y6 expressed low levels of CD103 and CD207, but both clusters uniformly  
196 expressed CD11a at high levels (**Fig. 2E**). CD14 and CD209 were expressed at only low levels  
197 in all clusters, but both showed highest expression within the cDC3 cluster Y5 (**Fig. S2D**). Finally,  
198 CD5, which has been used as a specific surface marker of human blood cDC2 vs. cDC3 (Bourdely  
199 et al., 2020; Cytlak et al., 2020; Dutertre et al., 2019; Yin et al., 2017), was expressed by only a  
200 small fraction of cells in both intestinal cDC2 cluster Y2 and cDC3 cluster Y6 (**Fig. S2E**). To define  
201 intestinal cDC2 vs cDC3 using surface markers, the co-expression of CD103, CD207 and CD11a  
202 was analysed using CITE-seq, and cDC2 were defined as CD103<sup>+</sup> and/or CD207<sup>+</sup> CD11a<sup>-/low</sup>  
203 cells, while cDC3 were defined as CD103<sup>-</sup> CD207<sup>low/-</sup> CD11a<sup>hi</sup> cells (**Fig. 2F**). Clusters Y3 and Y4  
204 both showed a mix of CD103<sup>+</sup> CD207<sup>+</sup> CD11a<sup>-</sup> and CD103<sup>-</sup> CD207<sup>-</sup> CD11a<sup>+</sup> expression (**Fig.**



205 **S2F**). Thus, putative cDC3 can be distinguished from cDC2 in the human intestinal LP by high  
206 expression of CD11a, low expression of CD103, and moderate-to-low expression of CD207.

207

### 208 **The human intestinal LP contains precursors of cDC1, cDC2 and cDC3**

209 Conventional DC are derived from pre-cDC, and recent studies have identified committed  
210 precursors of cDC1 (pre-cDC1), cDC2 (pre-cDC2), and, more recently, cDC3 (pre-cDC3)  
211 (Bourdely et al., 2020), as well as uncommitted pre-cDC precursors in human peripheral bone  
212 marrow, blood (Breton et al., 2015; Cytlak et al., 2020; See et al., 2017; Villani et al., 2017), and  
213 tonsils (Durand et al., 2019). Given that some intestinal cDC clusters in this dataset shared  
214 characteristics with cDC precursors (Fig. 2) - and to explore the relationships between these cells  
215 and mature cDC subsets - the cDC1, cDC2, and cDC3 clusters were computationally isolated and  
216 re-clustered together, and tSpace (Dermadi et al., 2020) was used to perform trajectory analysis.  
217 The tSpace principle components were used for a trajectory-based clustering and visualisation  
218 by 2D representation of 3-dimensional tSpace UMAP (Flat tUMAP). Cells of the previous cDC2  
219 (Y2) and cDC3 (Y5/6) clusters again grouped together in this clustering, while cDC1 were  
220 separate, but all subsets extended individual branches to meet at the connection between Y1,  
221 Y4, and cDC1 (**Fig. 3A**). The clusters at the tips of these branches expressed a proliferation  
222 signature, defined by high expression of the cell-cycle-associated genes, including *STMN1*,  
223 *KIAA0101*, and *MKI67*, which is characteristic of pre-cDC (**Fig. 3B**) (Balan et al., 2018; Brown et  
224 al., 2019; Chen et al., 2016; Durand et al., 2019; Ma et al., 2019). By re-clustering all cDC at high  
225 resolution, 42 new cDC clusters were identified (**Fig S3A**), and to focus on putative cDC  
226 precursors, all clusters outside of the proliferating branches were grouped into putative mature  
227 cDC1, cDC2, and cDC3 clusters (**Fig. 3C**), and these identities were confirmed by expression of  
228 the signature genes *CLEC9A*, *IRF4*, and *C1QA* (**Fig. 3D**). The remaining clusters D1, D3, D4,  
229 and D7-D9 all expressed a proliferation signature, while clusters D1, D3, D4 and D7 all expressed

230 low levels of MHCII genes (**Fig. 3E**), which has been described for mouse and human pre-cDC  
231 (Cabeza-Cabrerizo et al., 2021; Villani et al., 2017). Clusters D3, D4 and D7 also expressed low  
232 levels of the CD11c gene *ITGAX*, compared with mature cDC2/3 (**Fig. 3E**), which is characteristic  
233 of early cDC precursors (Cytlak et al., 2020). Clusters D3 and D7 expressed high levels of the  
234 pDC-associated genes *LILRA4* and *GZMB* (**Fig. 3E**), which suggests that these may be the most  
235 developmentally close to early pre-cDC (See et al., 2017). Finally, clusters D1, D3, D7 and D8  
236 expressed the highest relative 'stemness' score, composed of 20 genes expressed in our dataset  
237 (*BUB1*, *CCND2*, *CDC6*, *CDT1*, *CKS2*, *COL18A1*, *CSRP2*, *DTYMK*, *HELLS*, *KPNA2*, *MCM2*,  
238 *MCM4*, *MCM5*, *NAP1L1*, *PCNA*, *RRM2*, *SHROOM3*, *SMO*, *TOP2A*, *TTK*) out of 40 genes which  
239 were previously identified as forming a general 'stemness' signature (Koeva et al., 2011) (**Fig.**  
240 **S3B**). Thus, clusters D1, D3, D4, D7 and D8 are a heterogeneous mix of proliferating cells, each  
241 showing multiple features of pre-cDC. Clusters D9 and D10 expressed *CCR7*, *CD80* (B7-1),  
242 *LAMP3* (DC-LAMP), and *CD80*, as well as *CD207* and *C1QA* (**Fig. 3E**), were therefore identified  
243 as mixed clusters of migratory cDC2/3.

244

### 245 **Heterogeneity of human intestinal LP pre-cDC**

246 The pre-cDC cluster D1 expressed the cDC1-associated genes *IRF8*, *BATF3*, *CADM1*, *ID2* and  
247 *CLEC9A*, as well as moderate levels of *XCR1* (**Fig. 3D and E**). Cluster D1 connected to D2 then  
248 to mature cDC1 in the tUMAP embedding, with the former expressing higher levels of *RUNX3*,  
249 *THBD*, and the pre-cDC-associated *CLEC4C* (See et al., 2017) (**Fig. 3E**). In contrast, cluster D2  
250 and the mature cDC1 expressed higher levels of *XCR1* and *CADM1* than cluster D1 (**Fig. 3E**). In  
251 agreement with the mouse literature (Grajales-Reyes et al., 2015), *NR4A1* and *ATF3* were  
252 upregulated during the transition from D2 to the mature cDC1 cluster (**Fig. 3C**). Collectively, these  
253 results suggest that cluster D1 and D2 may represent early and late pre-cDC1, respectively.

254

255 The pre-cDC clusters D3 and D4 expressed genes associated with the cDC2 lineage, including  
256 *IRF4*, *CD1C* and *IL-22RA2*; transcription factors associated with haematopoiesis, including  
257 *PRDM16* (Tang-Huau et al., 2018), *KIT* (Thorén et al., 2008), *SOX4* (Ma et al., 2019) and *CXXC5*  
258 (Joshi et al., 2020); *S100B* and *LTB*, which are expressed on proliferating pre-cDC in the human  
259 tonsil (Durand et al., 2019); and *NGFR* and *CDH1*, the proteins of which have been previously  
260 identified as cell surface markers of pre-cDC (Dutertre et al., 2019) (**Fig. 3E**). Cluster D4 did not  
261 express cell-cycle genes to the same extent as D3, but expressed the highest level of the  
262 haematopoiesis genes, and the highest level of the pDC-associated genes *LILRA4* and *GZMB*  
263 (**Fig. 3E**). D4 also expressed low levels of *CD1C*, which aligns with previous data on early pre-  
264 cDC subsets (See et al., 2017) (**Fig. 3E**). Thus, clusters D3 and D4 appear to be distinct subsets  
265 of pre-cDC2, with D4 perhaps representing an earlier precursor.

266  
267 Proliferating clusters D7, D8 and D9, which were connected in the tUMAP embedding to mature  
268 cDC3 (**Fig. 3C**), all expressed cDC3 markers such as *C1QA*, *CD14*, and *CD163* (**Fig. 3D and E**).  
269 These cells also expressed higher levels of several genes associated with pre-DC in blood,  
270 including *AXL* and *IL3RA* (Brown et al., 2019; Cytlak et al., 2020; See et al., 2017; Villani et al.,  
271 2017) although these are also expressed by the mature cDC3 (**Fig 3E**). Of these three clusters,  
272 D7 expressed the highest level of the cell-cycle genes and the myelopoiesis-associated gene  
273 *CD38*, and the lowest level of MHCII genes (**Fig. 3E**). Collectively, these results suggest that  
274 clusters D7-D9 represent a heterogeneous mix of pre-cDC3, with D7 perhaps representing the  
275 earliest precursor.

276  
277 To assess the direction in which the putative pre-cDC clusters might be related, RNA velocity of  
278 the clusters was analysed and overlaid on the tUMAP embedding. Analysis of RNA splicing  
279 patterns demonstrated a clear directionality between pre-cDC1 clusters D2 and D3, with a less

280 pronounced velocity to mature cDC1 cluster D4 (**Fig. 3F**). There was clear directionality from pre-  
281 cDC2 cluster D4 to mature pre-cDC2 and from pre-cDC3 cluster D7 to mature cDC3 (**Fig. 3F**).  
282 Directionality was unclear between the pre-cDC clusters D1, D3, D4 and D7, with D3 or D4  
283 seemingly upstream of D1 and D7 (**Fig. 3F**). The data showed similar results when ileal and  
284 colonic samples were analysed separately (**Fig. S3C**). To further analyse cluster relationships,  
285 the pseudotime of each cluster was analysed using the most proliferative cluster, D7, as the  
286 starting point for pseudotime calculation. The putative lineage-specific precursors (D1, D3/4, and  
287 D7) each had low pseudotime scores compared with their mature counterparts, supporting their  
288 identities as precursors, while the putative migratory clusters (D5 and D6) had the highest  
289 pseudotime scores, supporting their identities as highly mature cDC (**Fig. 3G**).

290

291

292

293

#### 294 **Characterising intestinal LP monocyte and macrophage populations**

295 Murine intestinal monocytes develop into macrophages along a ‘waterfall’ of phenotypic  
296 intermediates which is interrupted during inflammation, leading to the preferential accumulation  
297 of pro-inflammatory cells at the expense of mature macrophages (Bain et al., 2013, 2014;  
298 Desalegn and Pabst, 2019; Rivollier et al., 2012). To investigate whether a similar monocyte  
299 ‘waterfall’ exists in the human intestine LP, ileal and colonic LP cells identified as Mono/Mac in  
300 Fig. 1 were isolated and trajectory analysis was performed with tSpace (Dermadi et al., 2020).  
301 The tSpace principal components were used for trajectory-based reclustering and tUMAP  
302 embedding, which resulted in 11 Mono /Mac clusters (M1-M11) (**Fig. 4A**). DEG analysis of the  
303 trajectory-based clusters identified high levels of monocyte-associated genes, such as *S100A9*,  
304 *FCN1* and *VCAN* (Bujko et al., 2018; Villani et al., 2017), in cluster M1 (**Fig. 4B and C**). To

305 investigate the downstream developmental trajectories, pseudotime scoring was performed on  
306 the tSpace trajectories using the M1 monocyte cluster as the pseudotime starting point, and  
307 averaging all trajectories from there. This demonstrated a pseudotime trajectory from cluster M1,  
308 via M2-M3, then M4-M6, and ending at M7-M10 (**Fig. 4D**). Cluster M11 was considered too small  
309 to analyse pseudotime with confidence.

310  
311 To investigate heterogeneity of the monocyte-derived clusters, DEG analysis showed clusters M2  
312 and M3 as expressing intermediate levels of *S100A9*, *VCAN*, and *ITGAX* and low levels of *C1QC*,  
313 which we classified as early intermediate cells; clusters M4-6, which lacked expression of *S100A9*  
314 and *FCN1* and expressed intermediate levels of *ITGAX* and *C1QC*, which we classified as late  
315 intermediate cells; and cluster M7 and M8 that expressed high levels of *CD209* and *C1QC*, which  
316 is consistent with mature macrophages (Bujko et al., 2018; Schridde et al., 2017) (**Fig. 4B and**  
317 **C**). The two small clusters M9 and M10 shared some features with mature macrophages,  
318 including high expression of MHCII and C1Q genes, but expressed low levels of *CD209* and  
319 *CD163* (**Fig. 4B and C**). Finally, the smallest cluster, M11, expressed very high levels of cell-  
320 cycle associated genes including *MKI67* and *KIAA0101*, indicating that these represented a  
321 population of proliferating cells (**Fig. 4B and C**).

322  
323 In recent single-cell data, murine monocytes were found to develop into resident macrophages  
324 along two distinct paths, defined by the expression or absence of pro-inflammatory pathways  
325 (Desalegn and Pabst, 2019). To investigate this possibility in human intestinal Mono/Mac,  
326 signalling pathway activity was analysed using the Pathway RespOnsive GENes (PROGENy)  
327 package, which infers pathway activity within cells using expression levels of pathway response  
328 genes (Schubert et al., 2018) (**Fig. 4E**). PROGENy analysis showed activation of NF $\kappa$ B and TNF $\alpha$   
329 signalling pathways in the monocyte cluster M1 and in the early intermediate cluster M3, but not

330 in the parallel early intermediate cluster M2 (**Fig. 4E**). Consistent with this, cluster M3 expressed  
331 high levels of pro-inflammatory cytokines including *IL1B*, *CXCL8* (IL8), and *CCL4* (MIP-1 $\beta$ ), as  
332 well as the signalling protein *NFKBIA* (**Fig. 4B** and F). This dichotomy extended to late  
333 intermediate as well as mature macrophage clusters, with the late intermediate cluster M5 and  
334 the mature macrophage cluster M7 showing indications of enhanced NF $\kappa$ B and TNF signalling,  
335 and enhanced expression of higher pro-inflammatory cytokines, compared with other late  
336 intermediate and mature macrophage clusters (**Fig. 4B and F**). Clusters M3, M5 and M7 also  
337 showed higher activation of MAPK and EGFR pathways (**Fig. 4E**). In contrast, the late  
338 intermediate clusters M4 and M6, and the mature macrophage clusters M8 and M9, all showed  
339 evidence of increased activation of the JAK-STAT and WNT signalling pathways (**Fig. 4E**).  
340 Interestingly, three of the 4 mature macrophage clusters (M7-M9) showed evidence of responding  
341 to TGF $\beta$  signalling (**Fig. 4E**), consistent with previous work in mice (Schridde et al., 2017). These  
342 clusters also showed evidence of p53 pathway activation, which is involved in multiple aspects of  
343 cell function including cell-cycle arrest, and which was not active in the proliferating cluster M11  
344 (**Fig. 4E**). In contrast, M11 showed evidence of responding to oestrogen (**Fig. 4E**), consistent with  
345 findings that oestrogen may drive macrophage proliferation (Pepe et al., 2018).

346

347

348 As well as showing a putative pro-inflammatory phenotype, clusters M5 and M7 expressed the  
349 stimulus-response genes *FOS*, *JUN*, and *EGR1* (Bahrami and Drabløs, 2016) (**Fig. 4B and G**),  
350 and other transcription factors including *KLF2*, *KLF4* and *KLF6* (**Fig. 4B**). The Discriminant  
351 Regulon Expression Analysis (DoRothEA) package, which infers transcription factor activity from  
352 expression of downstream target genes, was used to further investigate this heterogeneity in  
353 transcription factor activity (Garcia-Alonso et al., 2019; Holland et al., 2020). This supported  
354 activity of transcription factors including Nuclear Factor kappa-light-chain-enhancer of activated

355 B cells (NFκB) and Activator Protein-1 (AP-1) in clusters M1, M3, M5, and M7, and additionally  
356 identified activity of Activating Transcription Factor (ATF) in clusters M5 and M7 (**Fig. S4A**). In  
357 contrast, clusters M4, M6, M8 and M9 showed inferred activity of the transcriptional repressor  
358 RE1-Silencing Transcription factor (REST), and the MHCII promoter-associated regulatory factor  
359 X5 (RFX5) (**Fig. S4A**). Interestingly, cluster M6 also expressed the stimulus-response genes and  
360 KLF genes (**Fig. 4B and G**), but this cluster showed activation of the JAK-STAT and WNT  
361 pathways instead of the NFκB, TNFα MAPK, and EGFR pathways (**Fig. 4E**), it expressed low  
362 levels of pro-inflammatory cytokines (**Fig. 4F**), and showed particularly low activation of *JUN* and  
363 *FOS* (**Fig. S4A**). Thus, clusters M3, M5, and M7 seem to share a stimulus-response and pro-  
364 inflammatory profile, while clusters M2, M4, and M6 seemed to share a less-inflammatory profile.  
365  
366 Clusters M5, M6, M7, and M10 also expressed the transcription factor *KLF2*, which has been  
367 implicated in efferocytosis, and clusters M6 and M7 expressed the efferocytosis-associated gene  
368 *STAB1*, suggesting they may be specialised for uptake of apoptotic cells (**Fig. 4H**)(Elliott et al.,  
369 2017). Two other efferocytosis-associated genes, *AXL* and *MERTK*, were expressed by clusters  
370 M4-M9 and M7-M9, respectively (**Fig. 4H**). Thus, the late intermediate clusters M4-M6 and mature  
371 macrophages M7-M9 seem to be involved in efferocytosis, but, in line with a recent study (Lantz  
372 et al., 2020), there is heterogeneity in the expression of genes involved.

373  
374 To understand how the intestinal macrophage subsets (M7-10) may be related to previously  
375 describe tissue resident macrophage subsets, we further explored genes differentially  
376 expressed by these subsets. The macrophage clusters M7, and, to a lesser extent, M8, were  
377 both enriched in gene signatures of perivascular macrophages (Silva et al., 2021), including  
378 *LYVE1*, *SIGLEC1* (CD169), *FOLR2*, and *MAF* (**Fig. 4B and I**), consistent with the finding that  
379 the majority of mature macrophages in the LP are found in a perivascular niche (Honda et al.,

380 2020). CD169<sup>+</sup> macrophages have also been observed in mouse intestines (Hiemstra et al.,  
381 2014), where they seem to play a role in surveillance of the vasculature (Kang et al., 2020).

382  
383 The small *CD163*<sup>lo</sup> mature macrophage cluster, M9, expressed relatively high levels of *CD4*, *C2*,  
384 and *ADAMDEC1* (**Fig. 4B and J**), and in this respect resembled non-monocyte-derived self-  
385 maintaining resident macrophages, as previously described in the murine intestine (De  
386 Schepper et al., 2018; Shaw et al., 2018). These cells also highly expressed matrix  
387 metalloproteinases, including *MMP9* and *MMP12* (**Fig. 4B and J**), which was also reported for  
388 self-maintaining murine intestinal macrophages (De Schepper et al., 2018), and these cells  
389 might therefore be involved in tissue remodelling or angiogenesis. The other *CD163*<sup>lo</sup>  
390 macrophages, in cluster M10, expressed genes associated with iron sequestration (*FTL*),  
391 vitamin A metabolism (*RBP1*), microglia (*PLP1*, *PMEPA1*, *GPM6B*) and fibrosis (*SPARC*), as  
392 well as the adipocyte-associated genes *ADIRF* and *SCD* (**Fig. 4B**), and showed poor activation  
393 of most of the response pathways (**Fig. 4E**) and transcription factor activity (**Fig. S4A**), so did  
394 not have a clear phenotype. They did however resemble adipose tissue macrophages in several  
395 respects (Frey and Vogel, 2011; Li et al., 2020), including activity of the TRAIL pathway (**Fig. 4E**)  
396 (Maixner et al., 2020).

397  
398 In summary, ileal and colonic LP Mono/Mac are highly heterogeneous, encompassing a  
399 differentiation spectrum from monocytes (M1) through early (M2, M3) and late (M4, M5, M6)  
400 intermediate cells, to mature macrophages (M7, M8), as well as small populations resembling  
401 self-maintaining macrophages (M9), adipose tissue-like macrophages (M10), and proliferating  
402 cells without a clear identity (M11). Monocytes appear to develop into macrophages via both a  
403 pro-inflammatory route (M1- M3- M5- M7) and a parallel less-inflammatory route (M1- M2- M4-  
404 M6- M8).



405

## 406 **Analysis of Mono/Mac subsets by surface marker expression**

407 To identify surface antigens that could be used to distinguish the different stages of intestinal  
408 monocyte development by flow cytometry, colonic CD14<sup>+</sup>CD1c<sup>lo</sup> cells were screened for surface  
409 antigens which showed heterogeneous expression, using the Legendscreen. Of 288 antibodies  
410 tested, colonic CD14<sup>+</sup>CD1c<sup>lo</sup> cells expressed heterogeneous levels of CD11a (LFA1/ITGAL),  
411 CD11b (ITGAM), CD11c (ITGAX), CD13 (ANPEP), CD18 (ITGB2), CD39 (ENTPD1), CD50  
412 (ICAM3), CD55 (DAF), CD81, CD89 (FCAR), CD90, CD163, CD206 (mannose receptor/MRC1),  
413 CD274 (PDL1), CD276, and CD301 (CLEC10A) (**Fig. S4B**), indicating that these could be used  
414 as surface markers to distinguish distinct subsets. Of these CD11c, CD11a, CD206, and CD55  
415 together with CD14 and CD1c were selected to use in a CITE-seq panel to determine their levels  
416 of expression on clusters M1-M11 (**Fig. 4K**). CD55 was highly expressed by the monocyte cluster  
417 M1, expressed at intermediate levels on early intermediate clusters M2 and M3, and was not  
418 expressed on late intermediate clusters M4 and M5, or mature Mac (**Fig. 4K**). CD11a was highly  
419 expressed on monocyte (M1) and early intermediate clusters (M2 and M3), and was expressed  
420 at intermediate levels on late intermediate clusters (M4 and M5) (**Fig. 4K**). In contrast, CD206  
421 was induced at the late intermediate stage of development and was maintained on mature  
422 macrophage clusters, but was not present on the small M9 and M10 clusters (**Fig. 4K**). CD1c was  
423 poorly expressed by monocytes and macrophages, but was expressed at moderate levels on all  
424 intermediate clusters (M2-M6). This aligned with the observed expression of cDC2-associated  
425 genes *CD1C*, *CD1E*, *CLEC10A*, and *FCER1A* in monocyte-derived intermediate clusters (**Fig.**  
426 **4B**). CD11c was expressed at moderate levels on monocytes and increased during development  
427 of intermediate clusters M2-M6, then it was expressed at moderate-to-high levels on clusters M8  
428 and M9 and low levels on M7 and M10 (**Fig. 4K**). Cluster M7 was distinguished from other mature  
429 macrophages by particularly high CD14 expression, while M9 and M10 could be identified as

430 uniquely CD206<sup>-</sup> CD11c<sup>+</sup> and CD206<sup>-</sup> CD11c<sup>-</sup> macrophages, respectively (**Fig. 4K**). In summary,  
431 a panel of surface markers was used to identify heterogeneity and likely developmental stage  
432 within intestinal monocytes and macrophages.

433

#### 434 **Site-specific differences in MNP subsets**

435 Given the non-redundant role individual MNP subsets play in intestinal homeostasis and disease,  
436 we used our scRNA-seq and CITE-seq analyses to design an antibody panel that would allow  
437 assessment of potential regional and inflammation-associated alterations in intestinal MNP  
438 subset composition by flow cytometry. To maximise the number of MNP subsets which could be  
439 analysed in small biopsy samples, we designed an antibody panel which would identify multiple  
440 MNP subsets by flow cytometry, in a single tube. Among the viable CD45<sup>+</sup> CD3<sup>-</sup> CD19<sup>-</sup> HLA-  
441 DR<sup>int/+</sup> cells, cDC2 were identified as CD14<sup>-</sup> CD141<sup>-</sup> CD1c<sup>+</sup> CD11a<sup>-</sup> CD103<sup>+</sup> cells, while cDC3  
442 were identified as CD14<sup>-</sup> CD141<sup>-</sup> CD1c<sup>+</sup> CD11a<sup>+</sup> CD103<sup>-</sup> cells (**Fig. 5A**). Using this panel, we  
443 additionally found that cDC2 exclusively expressed CD1a, while cDC3 exclusively expressed  
444 CLEC12A (**Fig. 5B**). When assessing subset frequencies in 10 matched ileal and colonic  
445 samples, cDC2 dominated the CD1c<sup>+</sup> DC population of the ileum, but cDC2 and cDC3 were  
446 present at equivalent frequencies in the colon (**Fig. 5C**). Thus, human intestinal CD1c<sup>+</sup> cells can  
447 be separated by flow cytometry into CD1c<sup>+</sup> CD103<sup>+</sup> CD1a<sup>+</sup> cDC2 and CD1c<sup>+</sup> CD11a<sup>hi</sup> CLEC12A<sup>+</sup>  
448 putative cDC3.

449

450 To identify the different Mono/Mac subsets, CD14<sup>int/+</sup> cells were divided into two fractions  
451 consisting of CD55<sup>+</sup> CD206<sup>-</sup> and CD55<sup>-</sup> CD206<sup>+/-</sup> cells (**Fig. 5D**). The CD55<sup>+</sup> CD206<sup>-</sup> cells  
452 contained HLA-DR<sup>int</sup> monocytes and HLA-DR<sup>+</sup> early intermediate cells. The CD55<sup>-</sup> CD206<sup>+/-</sup>  
453 fraction was first divided into CD11a<sup>+</sup> CD163<sup>-</sup> late intermediate and CD11a<sup>-</sup> CD163<sup>int/+</sup> mature  
454 macrophages (**Fig. 5D**). Finally, the macrophages were divided into CD163<sup>int</sup> CD14<sup>int</sup> and CD163<sup>hi</sup>

455 CD14<sup>hi</sup> macrophages. Although CD14 and CD163 showed a continuous spectrum of expression,  
456 there was a clear division between intestinal sites, with significantly more CD163<sup>int</sup> CD14<sup>int</sup>  
457 macrophages in the ileum than in the colon (**Fig. 5E**). The CD206<sup>-</sup> macrophage populations  
458 (related to scRNA-seq clusters M9 and M10) were too small to identify with confidence in  
459 individual patient samples. However, after concatenation of 10 matched ileal and colonic LP  
460 samples, CD55<sup>-</sup> CD11a<sup>-</sup> CD206<sup>-</sup> CD14<sup>int</sup> CD163<sup>int</sup> cells could be identified as 0.61% of ileal and  
461 1.71% of colonic LP macrophages, respectively (**Fig. S5C**).

462

### 463 **Inflammation-associated changes to MNP subset frequencies**

464 To assess the impact of intestinal inflammation on the relative abundance of MNP subsets in the  
465 intestinal LP, we analysed biopsies taken during routine endoscopic procedures for initial disease  
466 assessment or disease surveillance. Biopsies were taken from multiple sites per patient, and the  
467 extent of inflammation at each site was classified using standard IBD scoring (see Methods) as  
468 either quiescent, mild, or moderate. In these biopsies, there was a positive correlation of cDC3  
469 and a negative correlation of cDC2 with the severity of colonic inflammation (**Fig. 5F**), and a  
470 similar trend was found in the ileum (**Fig. S5D**). Analysis of cDC2 and cDC3 as a proportion of  
471 total CD45<sup>+</sup> lineage<sup>-</sup> HLA-DR<sup>+</sup> MNP showed that this was due to a reduction in cDC2 compared  
472 with total MNP, rather than a relative expansion of cDC3 (**Fig. S5E**).

473

474 Some of the IBD patients recruited were undergoing anti- $\alpha$ 4 $\beta$ 7 antibody (Vedolizumab) therapy,  
475 and in these patients we noticed a dramatic reduction of total CD1c<sup>+</sup> MNPs in biopsy samples  
476 (**Fig. 5G and H**). We found that patients treated with Vedolizumab had lower frequencies of both  
477 CD1c<sup>+</sup> CD103<sup>+</sup> cDC2 and CD1c<sup>+</sup> CD103<sup>-</sup> cDC3 in the intestinal LP (**Fig. 5I**), while they retained  
478 CD14<sup>+</sup> cells (Mono/Mac) (**Fig. S5F**). The loss of both cDC2 and cDC3 after Vedolizumab

479 treatment, while monocytes and macrophages were retained, supports the definition of human  
480 intestinal CD1c<sup>+</sup> CD103<sup>-</sup> MNP as a conventional DC subset, and not as monocyte-derived cells.

481

482 Finally, we also analysed Mono/Mac subset frequencies in digested biopsies taken from IBD  
483 patients using flow cytometry. Because cell numbers were lower in biopsies than in resection  
484 samples, CD55<sup>+</sup> CD206<sup>-</sup> HLA-DR<sup>int</sup> monocytes could not be reliably distinguished from CD55<sup>+</sup>  
485 CD206<sup>-</sup> HLA-DR<sup>+</sup> early intermediate cells, so both were collected together in the CD55<sup>+</sup> CD206<sup>-</sup>  
486 gate. We found that increased severity of endoscopic inflammation was associated with an  
487 increase in both combined monocyte/early intermediate and in late intermediate cells in the colon  
488 (**Fig. 5J**) and ileum (**Fig. S5G**). The frequency of late intermediate cells was slightly increased in  
489 quiescent IBD samples compared with non-IBD controls, and was equivalent between mild and  
490 moderate IBD inflammation. However, the frequency of combined monocyte/early intermediate  
491 cells was only increased when inflammation was present (**Fig. 5J and S5G**). Human intestinal  
492 monocyte-derived cells therefore act similar to those of the mouse in inflammation, with an  
493 increase of monocyte and intermediate cells, and a reduction of mature macrophages.

494

495

496

497

498

499

## 500 **Discussion**

501  
502 MNPs play critical roles in tolerance, immunity and inflammation at the intestinal barrier and  
503 characterizing the individual members of this family will be crucial for understanding immune  
504 responses in the gut during health and disease. Here, we used scRNA-seq to characterise MNPs  
505 of the human intestinal LP, which is the largest site of immune surveillance in the gut. Much  
506 research focus of the last decade has been spent on deciphering MNP subset identities in mice  
507 and humans, an undertaking that has been complicated by their overlapping phenotypes  
508 (Bogunovic et al., 2009; Cytlak et al., 2020; Dutertre et al., 2019; Guilliams et al., 2016; Satpathy  
509 et al., 2012; Schlitzer et al., 2015; Tamoutounour et al., 2012; Varol et al., 2009; Villani et al.,  
510 2017). Human MNPs are classically defined by their expression of HLA-DR and lack of specific  
511 lineage markers such as CD3 and CD19, and are usually further divided into CD14<sup>+</sup> Mono/Macs  
512 and CD14<sup>-</sup> cDC (Caër and Wick, 2020). Here we used a relatively non-stringent gating strategy  
513 to enrich cells by FACS sorting before sequencing, to ensure comprehensive capture of all MNP  
514 subsets, including any MHCII<sup>lo</sup> cells such as pre-cDC and monocytes.

515  
516 Together with clearly separate clusters of pDC and cDC1, a small population of FCGR3A<sup>+</sup> non-  
517 classical monocytes was also found on initial analysis, but whether these were in the intestinal  
518 parenchyma itself is unclear. Non-classical monocytes are generally thought to function as MNP  
519 patrolling the vasculature (Carlin et al., 2013) and we identified substantial numbers of vascular  
520 and lymphatic endothelial cells in our preparations. Although this suggests that at least some of  
521 the non-classical monocytes we found may have been within the vasculature, there is some  
522 evidence that non-classical monocytes can migrate into tissues including the intestine (Schleier  
523 et al., 2020). Thus, the exact location of these non-classical monocytes remains an open question.  
524 Unlike the cDC1, pDC and non-classical monocytes, the cDC2, cDC3, classical monocytes, and  
525 macrophages all showed a high degree of transcriptional overlap, and high resolution analysis

526 was required to reveal distinct clusters of these cells. At least part of this transcriptional overlap  
527 involved shared expression of stimulus-response-associated genes, including *FOS*, *JUN*, and  
528 *EGR1*, and antigen presentation genes, including MHCII and CD1 genes. Similarly, although we  
529 attempted to regress out the effect of cell-cycle-associated genes, these continued to represent  
530 confounding issues when attempting to separate cDC2, cDC3, and Mono/Mac into discrete  
531 clusters. To circumvent the effect of these dominant shared state-specific genes, we used high  
532 resolution clustering and an iterative process involving both biased and unbiased approaches, to  
533 define cell identities.

534

535 Using this strategy, we were able to discriminate defined populations expressing signature genes  
536 of classical monocytes, macrophages and cDC2, but we also found a group of cells which  
537 expressed both monocyte- and cDC2-associated genes. Human MNPs with these characteristics  
538 have historically been identified as monocyte-derived DC (“moDC”) (Tang-Huau and Segura,  
539 2019) and DC-like cells can be derived from human monocytes *in vitro* (Sallusto and  
540 Lanzavecchia, 1994). However, recent scRNA-seq analyses have revealed a unique cell with  
541 monocyte- and cDC2-associated characteristics, named cDC3 (Bourdely et al., 2020; Cytlak et  
542 al., 2020; Dutertre et al., 2019; Villani et al., 2017). By extending our scRNA-seq findings with flow  
543 cytometry and CITE-seq, we confirmed previous reports that two subsets of CD1c<sup>+</sup> intestinal  
544 cDC2-like cells could be defined based on their expression of CD103 (Bernardo et al., 2016;  
545 Jaensson et al., 2008; Mann et al., 2015; Watchmaker et al., 2014). In our hands, these separated  
546 into a population of CD103<sup>+</sup> CD1a<sup>+</sup> cells that were consistent with *bona fide* cDC2, and a  
547 population of CD103<sup>-</sup> CD11a<sup>+</sup> CLEC12A<sup>+</sup> cells which had the characteristics of cDC3. These  
548 cDC3 not only expressed a number of monocyte-associated genes and were enriched in the colon  
549 compared with the ileum, but also expanded relative to cDC2 during active IBD inflammation. This  
550 could perhaps be explained by their expression of higher levels of *SELL* (coding for L-selectin),

551 an adhesion molecule which has been associated with myeloid cell migration to the inflamed  
552 intestine (Habtezion et al., 2016).

553

554 It should be noted that although the cDC3 we identified expressed monocyte-associated genes,  
555 it seems unlikely that they are derived from monocytes, as their numbers were significantly  
556 reduced in IBD patients that had been treated with anti-integrin  $\alpha 4\beta 7$  antibody (Vedolizumab)  
557 therapy, an intervention which we and others have shown does not affect monocyte proportions  
558 in the LP (Schleier et al., 2020). In contrast,  $\alpha 4\beta 7$  has been shown to play a role in the homing  
559 of cDC to the murine intestine (Villablanca et al., 2014) and our Vedolizumab-treated patients  
560 showed reduced proportions of cDC2. These findings have potential implications for the use of  
561 anti-integrin  $\alpha 4\beta 7$  as a long-term IBD therapeutic, as although blocking the migration of pro-  
562 inflammatory cDC activity into the gut could be beneficial, cDC are also crucial for the induction  
563 of tolerance to the microbiota in the gut (Ohnmacht et al., 2009; Travis et al., 2007; Worbs et al.,  
564 2006).

565

566 Although it remains possible that CD1c<sup>+</sup> CD103<sup>+</sup> and CD1c<sup>+</sup> CD103<sup>-</sup> MNP in the intestine merely  
567 represent different states of cDC2, cDC3 in humans have recently been described as forming a  
568 distinct lineage from cDC2 (Cytlak et al., 2020). In support of this possibility, we identified distinct  
569 populations of potential cDC precursors in the LP, including pre-cDC1, pre-cDC2, and pre-cDC3.  
570 These clusters showed low expression of MHCII genes, high expression of cell-cycle-associated  
571 genes and mixed expression of other hematopoietic and pre-cDC-associated genes. As well as  
572 the MHCII<sup>lo</sup> clusters, there were other proliferating, closely related clusters which also expressed  
573 cell-cycle genes to different extents, which could be developmentally intermediate or immature  
574 cDC. Recent work has suggested that cDC3 develop along a distinct developmental trajectory  
575 from cDC1 and cDC2 (Cytlak et al., 2020), but here, the developmental relationships between the

576 proliferating cDC/pre-cDC clusters was not clear. These findings suggest that a variety of different  
577 DC precursors may be present in the normal human intestinal LP. However, confirmation of this  
578 idea will require formal exploration of progenitor capacity by appropriate methods *in vitro* or *in*  
579 *vivo*.

580

581 In the mouse intestine, monocytes differentiate into macrophages through intermediate stages in  
582 what is known as the macrophage 'waterfall' (Bain et al., 2013; Rivollier et al., 2012; Schridde et  
583 al., 2017; Tamoutounour et al., 2012). It has recently been suggested that a similar monocyte-  
584 macrophage differentiation continuum may also exist in the human ileal mucosa (Bujko et al.,  
585 2018). In support of this, we identified 11 clusters of Mono/Mac which included classical  
586 monocytes, three clusters of mature macrophages, and five clusters which appeared to be  
587 intermediate between these. These cells were defined as intermediates due to both expression  
588 of genes associated with monocytes and mature macrophage genes, and due to the pseudotime  
589 analysis. This concept was also supported by CITE-seq and flow cytometry analyses, which  
590 suggested a continuum in which CD55<sup>+</sup> CD206<sup>-</sup> HLA-DR<sup>lo</sup> monocytes differentiated into CD55<sup>+</sup>  
591 CD206<sup>-</sup> HLA-DR<sup>+</sup> early intermediates, CD55<sup>-</sup> CD11a<sup>int</sup> CD206<sup>+</sup> late intermediates, followed by two  
592 populations of CD11a<sup>-</sup> CD14<sup>int</sup> CD163<sup>int</sup> and CD14<sup>hi</sup> CD163<sup>hi</sup> macrophages. Using this panel we  
593 found that the small intestine contains a significantly higher proportion of the CD14<sup>int</sup> CD163<sup>int</sup>  
594 macrophages than the colon. However, a complete definition of these cells as developmentally  
595 related will depend on further analysis, such as tracing of donor cells in transplant patients (Bujko  
596 et al., 2018). Similarly, while the small CD163<sup>lo</sup> macrophage clusters M9 and M10 transcriptionally  
597 resembled self-maintaining and adipose tissue macrophages, respectively, confirmation of these  
598 identities will await validation using other methods.

599



600 Our trajectory analysis suggested that monocytes entering the LP may give rise to two parallel  
601 pathways of macrophage development. One pathway (M3-M5-M7) was characterised by clusters  
602 expressing higher expression levels of pro-inflammatory cytokines and stimulus response genes,  
603 as well as inferred activity of NFκB/TNFα/EGFR signalling pathways and NFκB/ATF/AP-1  
604 transcription factors. The other pathway (M2-M4-M6-M8)) included clusters which were  
605 phenotypically and transcriptionally similar to the first, but without expression of the  
606 proinflammatory cytokines and without activity of the NFκB/TNFα/EGFR signalling pathways and  
607 NFκB/ATF/AP-1 transcription factors. Instead, these clusters showed inferred activity of JAK-  
608 STAT and WNT pathways, and of the transcriptional repressor REST. The implications of this are  
609 unclear, but it could reflect monocyte-macrophage differentiation occurring within different  
610 anatomical or immunological niches in the LP. Work in mice has shown that macrophages in the  
611 LP and muscularis layers of the intestine may be distinguished by their pro- or anti-inflammatory  
612 phenotype respectively (Gabanyi et al., 2016; Viola and Boeckxstaens, 2020), while a population  
613 of CD169<sup>+</sup> macrophages with pro-inflammatory properties has been described near the crypt base  
614 of the LP (Hiemstra et al., 2014). Furthermore, there is increasing evidence from other tissues  
615 that monocyte-derived resident macrophages can acquire very different properties depending on  
616 the exact niche which they locate to, such as close to nerves, blood vessels or airways (Blériot et  
617 al., 2020). In our Mono/Mac clusters, there was heterogeneity in expression of surface markers,  
618 efferocytosis genes, cytokines, and inferred activity of signalling pathways and transcription  
619 factors. Whether similar anatomical factors constrain the development of these heterogeneous  
620 populations of macrophages identified in human intestinal LP remains to be elucidated. We also  
621 identified two parallel pathways of monocyte development, with all clusters of one pathway  
622 expressing higher levels of pro-inflammatory cytokines than their counterparts in the other  
623 pathway. This could suggest that, similar to the situation in mice (Desalegn and Pabst, 2019),

624 monocytes entering the human gut can quickly gain a steady state or a pro-inflammatory  
625 phenotype, depending on the local environment.

626

627 Accumulation of pro-inflammatory, CD14<sup>+</sup> HLADR<sup>int</sup> cells is a characteristic feature of active  
628 inflammatory bowel disease (Jones et al., 2018; Martin et al., 2019) and recent studies have  
629 reported single-cell analyses of human intestinal MNP in IBD, as part of total leukocyte analyses  
630 (Martin et al., 2019; Rubin et al., 2019; Smillie et al., 2019). However, the number of MNP cells  
631 was small in these studies and there was no consensus on the exact nature of these cells, nor  
632 how they correspond to putative counterparts in the healthy gut. Here we confirmed the  
633 accumulation of CD14<sup>+</sup> HLADR<sup>int</sup> monocytes and monocyte-derived intermediates in both colonic  
634 and ileal LP during active IBD, along with fewer CD14<sup>int</sup> and CD14<sup>hi</sup> macrophages. Late  
635 intermediates appeared to expand in response to milder inflammation than monocytes and early  
636 intermediates, while monocytes/early intermediates seemed to only expand in more severe  
637 inflammation. The failure of monocytes to develop into mature macrophages in inflamed intestine  
638 was initially thought to reflect a block during the intermediate stages of differentiation (Bain et al.,  
639 2013; Rivollier et al., 2012). However, more recent work in mice has suggested that monocytes  
640 begin to follow an alternative pathway of development as soon as they enter the inflamed intestine  
641 (Desalegn and Pabst, 2019). Our findings support a model in which monocytes immediately  
642 respond to different environments as they enter the gut, and they suggest that this may be  
643 occurring constantly in the steady-state intestine. Here we have provided an overview of the  
644 developmental trajectory and heterogeneity of monocyte-derived cells in the intestinal LP, and we  
645 have identified novel markers which can be used to interrogate these cells.

646

647 In summary, our single-cell studies of MNP in carefully isolated LP emphasise the heterogeneity  
648 of these cells in both health and disease, and show that this may also differ depending on the

649 gut segment being examined. By identifying novel genetic and phenotypic markers, our work  
650 should provide useful information for further studies of how monocytes, macrophages and DC  
651 subsets might contribute to regulation of immune responses in the intestine.

652

### 653 **Acknowledgments**

654 We thank all patients and collaborating staff at Herlev hospital, and in particular the  
655 Gastroenterology Team (Department of Pathology) for help in providing tissue samples.  
656 Sequencing was performed at the National Genomics Infrastructure (NGI) and Science for Life  
657 Laboratory SNP&SEQ Technology Platform in Uppsala (supported by the Swedish Research  
658 Council and the Knut and Alice Wallenberg Foundation). We thank Dr J Rizk (Copenhagen  
659 University) for valuable guidance regarding signalling pathways. This work was supported by a  
660 grant from the Lundbeck foundation (R155-2014-4184), Denmark, to WW.A and S.B, the Danish  
661 Research Council (Sapere Aude III senior researcher grant 1331-00136B to W.W.A), and the  
662 Swedish Medical Research Council (2017-02072) and the Swedish Cancerfonden (18 0598) to  
663 W.W.A.

664

665

666

667 **Materials and Methods**

668  
669 **Methods**

670 **HUMAN SUBJECTS**

671 Resection samples were taken with informed consent from patients undergoing colorectal cancer  
672 surgery, as approved by the Videnskabetiske Komité for Region Hovedstaden, ethical  
673 permission H-3-2013-118. Resection tissues were taken at least 20 cm distant from any tumours  
674 present.

675  
676 Biopsy samples were obtained with informed consent from adult IBD patients attending routine  
677 colonoscopy for initial disease surveillance or ongoing disease assessment (Table S2 for  
678 anonymised patient information) at the Western General Hospital, Edinburgh, UK, after informed  
679 consent under existing approvals (REC:19/ES/0087). A diagnosis of IBD was made using  
680 standard criteria (Leonard-Jones), with all patients part of the Lothian IBD registry (Jones et al.,  
681 2019). Endoscopic assessment of disease severity for each biopsy site was performed by  
682 clinicians using the Mayo endoscopic subscore for UC or the simple endoscopic score (SES-CD)  
683 for CD. Each biopsy site was classed as quiescent, mild, moderate or severe endoscopic activity  
684 to enable comparison across IBD subtypes, and 3-5 biopsies were taken for analysis per site.

685  
686 **METHOD DETAILS**

687 **Tissue processing**

688 Samples were processed as described previously (Jørgensen et al., 2021). Briefly, resection  
689 samples were taken at least 10 cm distant from tumours, where present. The muscularis externa  
690 was removed using curved surgical scissors and the remaining tissue was incubated in a 370rpm  
691 shaking incubator twice for 10 min at 37°C in RPMI-5 (RPMI/5% FCS/1% penicillin and  
692 streptomycin) containing 4 mM DTT, to remove mucus. Macroscopically visible submucosa (SM)

693 was trimmed away using scissors. The mucosa was then separated from the underlying SM under  
694 a stereo microscope using forceps. Epithelial cells were removed from the remaining mucosa by  
695 shaking four times in Ca<sup>2+</sup> and Mg<sup>2+</sup> - free HBSS containing 1% penicillin and streptomycin and  
696 5 mM EDTA at 37°C, for 10 min each time. Any remaining ILF present in the mucosa were then  
697 dissected out using a scalpel under a stereo microscope with a transmitted light source. The  
698 remaining GALT-free LP was cut into 2-4 mm<sup>2</sup> pieces prior to digestion. A single-cell suspension  
699 of isolated LP was generated by shaking tissues at 370 rpm in a 37°C incubator in RPMI-5  
700 containing 30 µg/ml DNase and 5 mg/ml collagenase D or 2.5 mg/ml Liberase TM for 45 min, at  
701 37°C. The suspension was passed through a 100 µm filter before washing twice in fresh media  
702 and centrifuging to form a pellet.

703

#### 704 **Flow cytometry**

705 Cell suspensions were stained with the antibodies indicated (Table S3) in Brilliant stain buffer (BD  
706 Biosciences) containing 4% normal mouse serum according to standard techniques. The cells  
707 were stained with 7-AAD and analyzed on an LSR Fortessa 2 (BD Biosciences) using Flowjo  
708 software (Treestar).

709

710 For the Legendscreen assay (Biolegend), each antibody was first resuspended in 35 µl of FACS  
711 buffer (PBS with 5% FCS and 0.05% sodium azide). Up to 300x10<sup>6</sup> cells were stained with the  
712 antibody backbone panel (Table S4), washed and resuspended in PBS with 5% FCS. 40 µl of cell  
713 suspension was aliquoted into each well of V-bottom 96-well plates containing 10 ul of the PE-  
714 conjugated antibody per well. The cells were analysed using an LSR Fortessa 2 with High  
715 Throughput Sampler (BD).

716

#### 717 **Magnetic enrichment of MNP**

718 Single-cell suspensions to be used for single-cell sequencing were enriched for HLA-DR<sup>+</sup> cells  
719 using anti-HLA-DR microbeads (Miltenyi Biotec), as per the manufacturer's instructions. Briefly,  
720 cells were counted then centrifuged and resuspended in 80 µl cold MACS buffer (PBS with 0.5%  
721 BSA and 2mM EDTA) and 20 µl HLA-DR microbeads, per 1x10<sup>7</sup> total cells. Cells were stored on  
722 ice for 15 minutes then washed in 1 ml MACS buffer per 1x10<sup>7</sup> cells. Cells were centrifuged and  
723 resuspended in 500 µl fresh MACS buffer before adding to an LS MACS column. The flow-through  
724 was discarded and the HLA-DR<sup>+</sup> cells were washed through the column with 5 ml fresh buffer.

725

### 726 **Cell sorting**

727 Cells were counted, pelleted, and stained for flow cytometry as above. The cells were stained  
728 with anti-human CD45-BV421, CD3-PECF594, CD19-PECF594, HLA-DR-AF700, and 7-AAD  
729 was added before sorting to exclude dead cells. Viable CD45<sup>+</sup> HLA-DR<sup>int/+</sup> CD3<sup>-</sup> CD19<sup>-</sup> cells were  
730 sorted on a FACSMelody sorter (BD) into MACS buffer, before being counted and re-suspended  
731 in PBS with 0.4% BSA.

732

### 733 **CITE-seq**

734 For some samples, cells were first stained with barcode-labelled antibodies together with the  
735 antibodies used for sorting, before running the 10x protocol. The Totalseq-A antibodies used were  
736 anti-human CD1c (clone L161), CD14 (clone M5E2), CD11a (clone TS2/4), CD55 (clone JS11),  
737 CD5 (clone UCHT2), CD206 (clone 15-2), CD209 (clone 9E9A8), and CD11c (clone S-HCL-3),  
738 all from Biolegend.

739

### 740 **Single-cell 10x protocol**

741 Suspensions of sorted single cells were subjected to droplet-based massively parallel single-cell  
742 RNA sequencing using the Chromium Single Cell 3' Reagent Kit v3 following the manufacturer's

743 instructions (10x Genomics). The 10x Chromium Controller generated nanoliter-scale Gel Bead-  
744 In Emulsions (GEMs) droplets, where each cell was labeled with a specific barcode, and each  
745 transcript labeled with a unique molecular identifier (UMI). After reverse transcription (55°C for  
746 45min and 85 °C for 5min), the GEMs were broken down and the barcoded cDNA was purified  
747 with Dynabeads MyOne Silane beads (Thermofisher). The cDNA was amplified by PCR with 10x  
748 genomics and ADT additive primer (98 °C for 3min; 12 cycles of 98 °C for 15sec, 67 °C for 20sec  
749 and 72 °C for 1; 72 °C for 1min, end at 4 °C). The products were size separated with SPRIselect  
750 beads (Beckman Coulter) into fragments < 300nt containing antibody derived tags (ADTs) and >  
751 300nt containing cDNAs derived from cellular mRNA.

752

753 For sc-RNA libraries, 50 ng of amplified cDNA was used for final library preparation, consisting of  
754 enzymatic fragmentation, end repair, A-tailing, adaptor ligation and sample index PCR as per the  
755 manufacturer's instructions.

756

757 For epitope sequencing (CITE-seq), 2ul of ADTs were PCR amplified with Illumina compatible SI  
758 PCR and TrueSeq Small RNA RPIx primers (15 cycles). Final libraries were purified using  
759 SPRIselect beads.

760 Quality and quantity of the final libraries (sc-RNA and ADT) were measured using the Agilent  
761 2100 Bioanalyzer equipped with High Sensitivity DNA chip. Libraries were pooled according to  
762 the starting number of cells of each run (10% ADT + 90% sc-RNA).

763

764 SI-PCR primer: AATGATACGGCGACCACCGAGATCTACACTCTTTCCCTACACGACGC\*T\*C

765 ADT additive primer: CCTTGGCACCCGAGAATT\*C\*C

766 RPI1:CAAGCAGAAGACGGCATAACGAGATCGTGATGTGACTGGAGTTCCTTGGCACCCGAG

767 AATTC\*C\*A

768 RPI2:CAAGCAGAAGACGGCATAACGAGATACATCGGTGACTGGAGTTCCTTGGCACCCGAG

769 AATTC\*C\*A

770 RPI3:CAAGCAGAAGACGGCATAACGAGATGCCTAAGTGACTGGAGTTCCTTGGCACCCGAG

771 AATTC\*C\*A

772 RPI4:CAAGCAGAAGACGGCATAACGAGATTGGTCAGTGACTGGAGTTCCTTGGCACCCGAG

773 AATTC\*C\*A

774 \* indicates a phosphorothioate bond

775

## 776 **Sequencing**

777 Illumina sequencing was carried out at the Genomics Core Unit: Center of Excellence for  
778 Fluorescent Bioanalytics (KFB, University of Regensburg, Germany) and at the SNP&SEQ  
779 Technology Platform in Sweden which is part of the National Genomics Infrastructure (NGI),  
780 funded by the Swedish Council for Research Infrastructures and Science for Life Laboratory.  
781 Libraries were sequenced using HiSeq, NextSeq and NovaSeq systems (300 cycles), targeting a  
782 minimum of 30,000 read pairs per cell for sc-RNA and 3000 read pairs per cell for ADTs.

783

784

## 785 **Bioinformatic analysis**

786 Sequencing data was pre-processed and aligned with CellRanger (version 2.2.0 for the first  
787 patient samples and version 3.1.0 for all other samples)(Dobin et al., 2013; Zheng et al., 2017).  
788 The sequencing data from the samples stained with TotalSeq antibodies was processed with cite-  
789 seq count (Stoeckius et al., 2017). Each sample was then read into a Seurat (version 3.1.5) (Stuart  
790 et al., 2019) object in R (versions 3.5.1/4.0.1) (R Core Team, 2018) and processed by removing  
791 cells with exceptionally low or high UMI and gene counts (debris and doublets). The lower  
792 thresholds were set from 500-1000 genes per cell and the upper threshold were set from 3000-



793 6000. Furthermore, cells with mitochondrial gene content > 10% were also removed. The  
794 thresholds were set by studying UMI and gene counts, and mitochondrial gene content according  
795 to current best practise (Luecken and Theis, 2019). The debris removed from each sample was  
796 used as empty droplet information to normalize the protein level in the individual samples together  
797 with the isotype controls(Mulè et al., 2020). The normalized protein data was added to each of  
798 the relevant samples.

799

800 The scRNA data for each sample was normalized and cell cycle gene modules were calculated  
801 using the Seurat CellCycleScoring function and additionally a gene module representing cell cycle  
802 genes from the tool ccRemover by summing the raw counts of these genes per cell divided by  
803 the total number of reads per cell(Barron and Li, 2016). The top 3000 most variable genes were  
804 identified with the selection method vst.

805 After this initial data processing, all the samples were integrated with Seurat anchor integration  
806 and gene expression was scaled while regressing out effect of cell cycle, UMI counts, and  
807 mitochondrial gene content. The merged data were dimensionality reduced with PCA and the 15  
808 first PCs were chosen for downstream analysis. A shared nearest neighbour graph was  
809 constructed and used to cluster the data with Louvain clustering. The PCs were also used to  
810 dimensionality reduce the data further with UMAP for visualization purposes. The data were  
811 reclustered on described populations after removal of contaminating cell types and new UMAPs  
812 calculated.

813

814 The pseudobulk for heatmaps and PCA was performed with the Seurat AverageExpression  
815 function. The PCA on pseudobulk of clusters was performed only on genes from published gene  
816 signatures of blood DC2, blood monocytes and in vitro mo-Macs(Tang-Huau et al., 2018).  
817 Differential gene expression was calculated with Seurat FindMarkers for comparisons between

818 specific groups or FindAllMarkers for DEGs for all clusters both using the standard non-  
819 parameteric Wilcoxon rank sum test.

820

821 Trajectory inference was performed with tSPACE on PC spaces of indicated populations  
822 (Dermadi et al., 2020). The outputs were further dimensionality reduced with UMAP(Becht et al.,  
823 2019; McInnes et al., 2018) to 2 and 3 dimensions with distance metric set to Pearson. Clustering  
824 was performed with Louvain clustering for Seurat on the tSPACE PC output as input. RNA velocity  
825 estimates were calculated for T=1 and only included genes with splicing information also present  
826 in the variable genes and only on cells of interest (e.g. precursors). The information was  
827 embedded on top of 2D UMAPs from the tSPACE trajectories using n=400, scale=sqrt, grid.n=50  
828 and arrow.scale=2 (La Manno et al., 2018).

829 The data set from (Bourdely et al., 2020) was downloaded and processed as described in the  
830 methods section of that study. The blood data were then integrated with matching cell types from  
831 the lamina propria (identified monocytes and DC2-like cells) and differentially expressed genes  
832 were identified between tissues in each matching cell type.

833

## 834 **QUANTIFICATION AND STATISTICAL ANALYSIS**

835 Flow cytometry analyses were performed data were analysed using in Prism software (GraphPad).  
836 Details for, with the statistical tests used in each experiment can be found being shown in the  
837 relevant figure legends. Statistical significance was defined as \*p<0.05, \*\*p<0.01, \*\*\*p<0.001.  
838 Statistical analysis of sequencing data was performed in R as described in the bioinformatics  
839 section above.

840

841

842

## 843 **References**

- 844
- 845 Arroyo Portilla, C., Tomas, J., Gorvel, J., and Lelouard, H. (2021). From Species to Regional  
846 and Local Specialization of Intestinal Macrophages. *Front. Cell Dev. Biol.* **8**.
- 847 Bahrami, S., and Drabløs, F. (2016). Gene regulation in the immediate-early response process.  
848 *Adv. Biol. Regul.* **62**, 37–49.
- 849 Bain, C.C., and Schridde, A. (2018). Origin, differentiation, and function of intestinal  
850 macrophages. *Front. Immunol.* **9**, 1–15.
- 851 Bain, C.C., Scott, C.L., Uronen-Hansson, H., Gudjonsson, S., Jansson, O., Grip, O., Williams,  
852 M., Malissen, B., Agace, W.W., and Mowat, a M. (2013). Resident and pro-inflammatory  
853 macrophages in the colon represent alternative context-dependent fates of the same Ly6Chi  
854 monocyte precursors. *Mucosal Immunol.* **6**, 498–510.
- 855 Bain, C.C., Bravo-Blas, A., Scott, C.L., Perdiguero, E.G., Geissmann, F., Henri, S., Malissen, B.,  
856 Osborne, L.C., Artis, D., and Mowat, A.M. (2014). Constant replenishment from circulating  
857 monocytes maintains the macrophage pool in the intestine of adult mice. *Nat. Immunol.* **15**.
- 858 Balan, S., Arnold-Schrauf, C., Abbas, A., Couespel, N., Savoret, J., Imperatore, F., Villani, A.C.,  
859 Vu Manh, T.P., Bhardwaj, N., and Dalod, M. (2018). Large-Scale Human Dendritic Cell  
860 Differentiation Revealing Notch-Dependent Lineage Bifurcation and Heterogeneity. *Cell Rep.*  
861 **24**, 1902-1915.e6.
- 862 Barone, F., Vossenkamper, A., Boursier, L., Su, W., Watson, A., John, S., Dunn-Walters, D.K.,  
863 Fields, P., Wijetilleka, S., Edgeworth, J.D., et al. (2011). IgA-producing plasma cells originate  
864 from germinal centers that are induced by B-cell receptor engagement in humans.  
865 *Gastroenterology* **140**, 947–956.
- 866 Barron, M., and Li, J. (2016). Identifying and removing the cell-cycle effect from single-cell RNA-  
867 Sequencing data. *Sci. Rep.* **6**, 33892.
- 868 Becht, E., McInnes, L., Healy, J., Dutertre, C.-A., Kwok, I.W.H., Ng, L.G., Ginhoux, F., and  
869 Newell, E.W. (2019). Dimensionality reduction for visualizing single-cell data using UMAP. *Nat.*  
870 *Biotechnol.* **37**, 38–44.
- 871 Bernardo, D., Durant, L., Mann, E.R., Bassity, E., Montalvillo, E., Man, R., Vora, R., Reddi, D.,  
872 Bayiroglu, F., Fernández-Salazar, L., et al. (2016). Chemokine (C-C Motif) Receptor 2 Mediates  
873 Dendritic Cell Recruitment to the Human Colon but Is Not Responsible for Differences Observed  
874 in Dendritic Cell Subsets, Phenotype, and Function Between the Proximal and Distal Colon.  
875 *Cell. Mol. Gastroenterol. Hepatol.* **2**, 22-39.e5.
- 876 Bernardo, D., Chaparro, M., and Gisbert, J.P. (2018). Human Intestinal Dendritic Cells in  
877 Inflammatory Bowel Diseases. *Mol. Nutr. Food Res.* **62**, 1–8.
- 878 Blériot, C., Chakarov, S., and Ginhoux, F. (2020). Determinants of Resident Tissue Macrophage  
879 Identity and Function. *Immunity* **52**, 957–970.
- 880 Bogunovic, M., Ginhoux, F., Helft, J., Shang, L., Hashimoto, D., Greter, M., Liu, K., Jakubzick,  
881 C., Ingersoll, M. a, Leboeuf, M., et al. (2009). Origin of the lamina propria dendritic cell network.  
882 *Immunity* **31**, 513–525.
- 883 Bourdely, P., Anselmi, G., Vaivode, K., Ramos, R.N., Missolo-Koussou, Y., Hidalgo, S.,  
884 Tosselo, J., Nuñez, N., Richer, W., Vincent-Salomon, A., et al. (2020). Transcriptional and  
885 Functional Analysis of CD1c+ Human Dendritic Cells Identifies a CD163+ Subset Priming  
886 CD8+CD103+ T Cells. *Immunity* **53**, 335-352.e8.
- 887 Boursier, L., Gordon, J.N., Thiagamorthy, S., Edgeworth, J.D., and Spencer, J. (2005). Human  
888 Intestinal IgA Response Is Generated in the Organized Gut-Associated Lymphoid Tissue but  
889 Not in the Lamina Propria. *Gastroenterology* **128**, 1879–1889.
- 890 Breton, G., Lee, J., Zhou, Y.J., Schreiber, J.J., Keler, T., Pühr, S., Anandasabapathy, N.,  
891 Schlesinger, S., Caskey, M., Liu, K., et al. (2015). Circulating precursors of human CD1c+ and  
892 CD141+ dendritic cells. *J. Exp. Med.* **212**, 401–413.

893 Brown, C.C., Gudjonson, H., Pritykin, Y., Deep, D., Lavallée, V.P., Mendoza, A., Fromme, R.,  
894 Mazutis, L., Ariyan, C., Leslie, C., et al. (2019). Transcriptional Basis of Mouse and Human  
895 Dendritic Cell Heterogeneity. *Cell* 179, 846-863.e24.  
896 Bujko, A., Atlasy, N., Landsverk, O.J.B., Richter, L., Yaqub, S., Horneland, R., Øyen, O.,  
897 Aandahl, E.M., Aabakken, L., Stunnenberg, H.G., et al. (2018). Transcriptional and functional  
898 profiling defines human small intestinal macrophage subsets. *J. Exp. Med.* 215, 441–458.  
899 Cabeza-Cabrerizo, M., Cardoso, A., Minutti, C.M., Pereira da Costa, M., and Reis E Sousa, C.  
900 (2021). Dendritic Cells Revisited. *Annu. Rev. Immunol.* 131–166.  
901 Caër, C., and Wick, M.J. (2020). Human Intestinal Mononuclear Phagocytes in Health and  
902 Inflammatory Bowel Disease. *Front. Immunol.* 11, 410.  
903 Carlin, L.M., Stamatiades, E.G., Auffray, C., Hanna, R.N., Glover, L., Vizcay-Barrena, G.,  
904 Hedrick, C.C., Cook, H.T., Diebold, S., and Geissmann, F. (2013). Nr4a1-dependent Ly6C(low)  
905 monocytes monitor endothelial cells and orchestrate their disposal. *Cell* 153, 362–375.  
906 Carpentier, S., Vu Manh, T.P., Chelbi, R., Henri, S., Malissen, B., Haniffa, M., Ginhoux, F., and  
907 Dalod, M. (2016). Comparative genomics analysis of mononuclear phagocyte subsets confirms  
908 homology between lymphoid tissue-resident and dermal XCR1+ DCs in mouse and human and  
909 distinguishes them from Langerhans cells. *J. Immunol. Methods* 432, 35–49.  
910 Chapuy, L., Bsat, M., Sarkizova, S., Rubio, M., Therrien, A., Wassef, E., Bouin, M., Orlicka, K.,  
911 Weber, A., Hacohen, N., et al. (2019). Two distinct colonic CD14+ subsets characterized by  
912 single-cell RNA profiling in Crohn's disease. *Mucosal Immunol.* 12, 703–719.  
913 Chen, J., Schlitzer, A., Chakarov, S., Ginhoux, F., and Poidinger, M. (2016). Mpath maps multi-  
914 branching single-cell trajectories revealing progenitor cell progression during development. *Nat.*  
915 *Commun.* 7, 11988.  
916 Cytlak, U., Resteu, A., Pagan, S., Green, K., Milne, P., Maisuria, S., McDonald, D., Hulme, G.,  
917 Filby, A., Carpenter, B., et al. (2020). Differential IRF8 Transcription Factor Requirement  
918 Defines Two Pathways of Dendritic Cell Development in Humans. *Immunity* 53, 353-370.e8.  
919 Dermadi, D., Bscheider, M., Bjegovic, K., Lazarus, N.H., Szade, A., Hadeiba, H., and Butcher,  
920 E.C. (2020). Exploration of Cell Development Pathways through High-Dimensional Single Cell  
921 Analysis in Trajectory Space. *IScience* 23, 100842.  
922 Desalegn, G., and Pabst, O. (2019). Inflammation triggers immediate rather than progressive  
923 changes in monocyte differentiation in the small intestine. *Nat. Commun.* 10, 3229.  
924 Dobin, A., Davis, C.A., Schlesinger, F., Drenkow, J., Zaleski, C., Jha, S., Batut, P., Chaisson,  
925 M., and Gingeras, T.R. (2013). STAR: ultrafast universal RNA-seq aligner. *Bioinformatics* 29,  
926 15–21.  
927 Durand, M., Walter, T., Pirnay, T., Naessens, T., Gueguen, P., Goudot, C., Lameiras, S.,  
928 Chang, Q., Talaei, N., Ornatsky, O., et al. (2019). Human lymphoid organ cDC2 and  
929 macrophages play complementary roles in T follicular helper responses. *J. Exp. Med.* 216,  
930 1561–1581.  
931 Dutertre, C.A., Becht, E., Irac, S.E., Khalilnezhad, A., Narang, V., Khalilnezhad, S., Ng, P.Y.,  
932 van den Hoogen, L.L., Leong, J.Y., Lee, B., et al. (2019). Single-Cell Analysis of Human  
933 Mononuclear Phagocytes Reveals Subset-Defining Markers and Identifies Circulating  
934 Inflammatory Dendritic Cells. *Immunity* 51, 573-589.e8.  
935 Elliott, M.R., Koster, K.M., and Murphy, P.S. (2017). Efferocytosis Signaling in the Regulation of  
936 Macrophage Inflammatory Responses. *J. Immunol.* 198, 1387–1394.  
937 Fenton, T.M., Jørgensen, P.B., Niss, K., Rubin, S.J.S., Mörbe, U.M., Riis, L.B., Da Silva, C.,  
938 Plumb, A., Vandamme, J., Jakobsen, H.L., et al. (2020). Immune Profiling of Human Gut-  
939 Associated Lymphoid Tissue Identifies a Role for Isolated Lymphoid Follicles in Priming of  
940 Region-Specific Immunity. *Immunity* 52, 557-570.e6.  
941 Frey, S.K., and Vogel, S. (2011). Vitamin A Metabolism and Adipose Tissue Biology. *Nutrients*  
942 3, 27–39.

- 943 Gabanyi, I., Muller, P.A., Feighery, L., Oliveira, T.Y., Costa-Pinto, F. a., and Mucida, D. (2016).  
944 Neuro-immune Interactions Drive Tissue Programming in Intestinal Macrophages. *Cell* **164**,  
945 378–391.
- 946 Garcia-Alonso, L., Holland, C.H., Ibrahim, M.M., Turei, D., and Saez-Rodriguez, J. (2019).  
947 Benchmark and integration of resources for the estimation of human transcription factor  
948 activities. *Genome Res.*
- 949 Girard, M., Law, J.C., Edilova, M.I., and Watts, T.H. (2020). Type I interferons drive the  
950 maturation of human DC3s with a distinct costimulatory profile characterized by high GITRL.  
951 *Sci. Immunol.* **5**, eabe0347.
- 952 Goudot, C., Coillard, A., Villani, A.C., Gueguen, P., Cros, A., Sarkizova, S., Tang-Huau, T.L.,  
953 Bohec, M., Baulande, S., Hacothen, N., et al. (2017). Aryl Hydrocarbon Receptor Controls  
954 Monocyte Differentiation into Dendritic Cells versus Macrophages. *Immunity* **47**, 582-596.e6.
- 955 Grajales-Reyes, G.E., Iwata, A., Albring, J., Wu, X., Tussiwand, R., KC, W., Kretzer, N.M.,  
956 Briseño, C.G., Durai, V., Bagadia, P., et al. (2015). Batf3 maintains autoactivation of Irf8 for  
957 commitment of a CD8 $\alpha$ + conventional DC clonogenic progenitor. *Nat. Immunol.* **16**, 708–717.
- 958 Williams, M., Dutertre, C.-A., Scott, C.L., McGovern, N., Sichen, D., Chakarov, S., Van  
959 Gassen, S., Chen, J., Poidinger, M., De Prijck, S., et al. (2016). Unsupervised High-Dimensional  
960 Analysis Aligns Dendritic Cells across Tissues and Species. *Immunity* **45**, 669–684.
- 961 Habtezion, A., Nguyen, L.P., Hadeiba, H., and Butcher, E.C. (2016). Leukocyte Trafficking to  
962 the Small Intestine and Colon. *Gastroenterology* **150**, 340–354.
- 963 Hiemstra, I.H., Beijer, M.R., Veninga, H., Vrijland, K., Borg, E.G.F., Olivier, B.J., Mebius, R.E.,  
964 Kraal, G., and Den Haan, J.M.M. (2014). The identification and developmental requirements of  
965 colonic CD169+ macrophages. *Immunology* **142**, 269–278.
- 966 Holland, C.H., Tanevski, J., Perales-Patón, J., Gleixner, J., Kumar, M.P., Mereu, E., Joughin,  
967 B.A., Stegle, O., Lauffenburger, D.A., Heyn, H., et al. (2020). Robustness and applicability of  
968 transcription factor and pathway analysis tools on single-cell RNA-seq data. *Genome Biol.* **21**,  
969 36.
- 970 Honda, M., Surewaard, B.G.J., Watanabe, M., Hedrick, C.C., Lee, W.-Y., Brown, K., McCoy,  
971 K.D., and Kubes, P. (2020). Perivascular localization of macrophages in the intestinal mucosa is  
972 regulated by Nr4a1 and the microbiome. *Nat. Commun.* **11**, 1329.
- 973 Jaensson, E., Uronen-Hansson, H., Pabst, O., Eksteen, B., Tian, J., Coombes, J.L., Berg, P.-L.,  
974 Davidsson, T., Powrie, F., Johansson-Lindbom, B., et al. (2008). Small intestinal CD103+  
975 dendritic cells display unique functional properties that are conserved between mice and  
976 humans. *J. Exp. Med.* **205**, 2139–2149.
- 977 Joeris, T., Müller-Luda, K., Agace, W.W., and Mowat, A.M. (2017). Diversity and functions of  
978 intestinal mononuclear phagocytes. *Mucosal Immunol.* 1–20.
- 979 Jones, G.-R., Bain, C.C., Fenton, T.M., Kelly, A., Brown, S.L., Ivens, A.C., Travis, M.A., Cook,  
980 P.C., and MacDonald, A.S. (2018). Dynamics of Colon Monocyte and Macrophage Activation  
981 During Colitis. *Front. Immunol.* **9**.
- 982 Jones, G.-R., Lyons, M., Plevris, N., Jenkinson, P.W., Bisset, C., Burgess, C., Din, S., Fulforth,  
983 J., Henderson, P., Ho, G.-T., et al. (2019). IBD prevalence in Lothian, Scotland, derived by  
984 capture-recapture methodology. *Gut* [gutjnl-2019-318936](https://doi.org/10.1136/gutjnl-2019-318936).
- 985 Jørgensen, P.B., Fenton, T.M., Mørbe, U.M., Riis, L.B., Jakobsen, H.L., Nielsen, O.H., and  
986 Agace, W.W. (2021). Identification, isolation and analysis of human gut-associated lymphoid  
987 tissues. *Nat. Protoc.*
- 988 Joshi, H.R., Hill, H.R., Zhou, Z., He, X., Voelkerding, K. V., and Kumánovics, A. (2020).  
989 Frontline Science: Cxcr5 expression alters cell cycle and myeloid differentiation of mouse  
990 hematopoietic stem and progenitor cells. *J. Leukoc. Biol.* **108**, 469–484.
- 991 Kang, B., Alvarado, L.J., Kim, T., Lehmann, M.L., Cho, H., He, J., Li, P., Kim, B.H., Larochelle,  
992 A., and Kelsall, B.L. (2020). Commensal microbiota drive the functional diversification of colon


- 993 macrophages. *Mucosal Immunol.* *13*, 216–229.
- 994 Koeva, M., Forsberg, E.C., and Stuart, J.M. (2011). Computational Integration of Homolog and  
995 Pathway Gene Module Expression Reveals General Stemness Signatures. *PLoS One* *6*,  
996 e18968.
- 997 Lantz, C., Radmanesh, B., Liu, E., Thorp, E.B., and Lin, J. (2020). Single-cell RNA sequencing  
998 uncovers heterogenous transcriptional signatures in macrophages during efferocytosis. *Sci.*  
999 *Rep.* *10*, 14333.
- 1000 Li, Y., Yun, K., and Mu, R. (2020). A review on the biology and properties of adipose tissue  
1001 macrophages involved in adipose tissue physiological and pathophysiological processes. *Lipids*  
1002 *Health Dis.* *19*, 1–9.
- 1003 Lim, K.P.H., Milne, P., Poidinger, M., Duan, K., Lin, H., McGovern, N., Abhyankar, H., Zinn, D.,  
1004 Burke, T.M., Eckstein, O.S., et al. (2020). Circulating CD1c+ myeloid dendritic cells are potential  
1005 precursors to LCH lesion CD1a+CD207+ cells. *Blood Adv.* *4*, 87–99.
- 1006 Luecken, M.D., and Theis, F.J. (2019). Current best practices in single-cell RNA-seq analysis: a  
1007 tutorial. *Mol. Syst. Biol.* *15*.
- 1008 Ma, W., Lee, J., Backenroth, D., Zhou, Y.J., Bush, E., Sims, P., Liu, K., and Shen, Y. (2019).  
1009 Single cell RNA-Seq reveals pre-cDCs fate determined by transcription factor combinatorial  
1010 dose. *BMC Mol. Cell Biol.* *20*, 1–14.
- 1011 Maixner, N., Pecht, T., Haim, Y., Chalifa-Caspi, V., Goldstein, N., Tarnovscki, T., Liberty, I.F.,  
1012 Kirshtein, B., Golan, R., Berner, O., et al. (2020). A trail-tl1a paracrine network involving  
1013 adipocytes, macrophages, and lymphocytes induces adipose tissue dysfunction downstream of  
1014 e2f1 in human obesity. *Diabetes* *69*, 2310–2323.
- 1015 Mann, E.R., Bernardo, D., English, N.R., Landy, J., Al-Hassi, H.O., Peake, S.T., Man, R., Elliott,  
1016 T.R., Spranger, H., Lee, G.H., et al. (2015). Compartment-specific immunity in the human gut:  
1017 properties and functions of dendritic cells in the colon versus the ileum. *Gut* *140*, 169.
- 1018 La Manno, G., Soldatov, R., Zeisel, A., Braun, E., Hochgerner, H., Petukhov, V., Lidschreiber,  
1019 K., Kastrioti, M.E., Lönnerberg, P., Furlan, A., et al. (2018). RNA velocity of single cells. *Nature*  
1020 *560*, 494–498.
- 1021 Martin, J.C., Chang, C., Boschetti, G., Ungaro, R., Giri, M., Grout, J.A., Gettler, K., Chuang, L.  
1022 shiang, Nayar, S., Greenstein, A.J., et al. (2019). Single-Cell Analysis of Crohn's Disease  
1023 Lesions Identifies a Pathogenic Cellular Module Associated with Resistance to Anti-TNF  
1024 Therapy. *Cell* *178*, 1493-1508.e20.
- 1025 Masahata, K., Umemoto, E., Kayama, H., Kotani, M., Nakamura, S., Kurakawa, T., Kikuta, J.,  
1026 Gotoh, K., Motooka, D., Sato, S., et al. (2014). Generation of colonic IgA-secreting cells in the  
1027 caecal patch. *Nat. Commun.* *5*, 3704.
- 1028 McInnes, L., Healy, J., Saul, N., and Großberger, L. (2018). UMAP: Uniform Manifold  
1029 Approximation and Projection. *J. Open Source Softw.*
- 1030 Miller, J.C., Brown, B.D., Shay, T., Gautier, E.L., Jojic, V., Cohain, A., Pandey, G., Leboeuf, M.,  
1031 Elpek, K.G., Helft, J., et al. (2012). Deciphering the transcriptional network of the dendritic cell  
1032 lineage. *Nat. Immunol.* *13*, 888–899.
- 1033 De Monte, A., Olivieri, C.V., Vitale, S., Bailleux, S., Castillo, L., Giordanengo, V., Maryanski,  
1034 J.L., Segura, E., and Doglio, A. (2016). CD1c-related DCs that express CD207/langerin, but are  
1035 distinguishable from Langerhans cells, are consistently present in human tonsils. *Front.*  
1036 *Immunol.* *7*, 1–10.
- 1037 Mörbe, U.M., Jørgensen, P.B., Fenton, T.M., von Burg, N., Riis, L.B., Spencer, J., and Agace,  
1038 W.W. (2021). Human gut-associated lymphoid tissues (GALT); diversity, structure, and function.  
1039 *Mucosal Immunol.*
- 1040 Mowat, A.M., and Agace, W.W. (2014). Regional specialization within the intestinal immune  
1041 system. *Nat. Rev. Immunol.* *14*, 667–685.
- 1042 Mulè, M., Martins, A., and Tsang, J. (2020). Normalizing and denoising protein expression data

- 1043 from droplet-based single cell profiling. Preprint.
- 1044 Na, Y.R., Stakenborg, M., Seok, S.H., and Matteoli, G. (2019). Macrophages in intestinal  
1045 inflammation and resolution: a potential therapeutic target in IBD. *Nat. Rev. Gastroenterol.*  
1046 *Hepatol.* *16*, 531–543.
- 1047 Ohnmacht, C., Pullner, A., King, S.B.S., Drexler, I., Meier, S., Brocker, T., and Voehringer, D.  
1048 (2009). Constitutive ablation of dendritic cells breaks self-tolerance of CD4 T cells and results in  
1049 spontaneous fatal autoimmunity. *J. Exp. Med.* *206*, 549–559.
- 1050 Pepe, G., Locati, M., Della Torre, S., Mornata, F., Cignarella, A., Maggi, A., and Vegeto, E.  
1051 (2018). The estrogen-macrophage interplay in the homeostasis of the female reproductive tract.  
1052 *Hum. Reprod. Update* *24*, 652–672.
- 1053 R Core Team (2018). R: A Language and Environment for Statistical Computing.
- 1054 Rivollier, A., He, J., Kole, A., Valatas, V., and Kelsall, B.L. (2012). Inflammation switches the  
1055 differentiation program of Ly6Chi monocytes from antiinflammatory macrophages to  
1056 inflammatory dendritic cells in the colon. *J. Exp. Med.* *209*, 139–155.
- 1057 Rubin, S.J.S., Bai, L., Haileselassie, Y., Garay, G., Yun, C., Becker, L., Streett, S.E., Sinha,  
1058 S.R., and Habtezion, A. (2019). Mass cytometry reveals systemic and local immune signatures  
1059 that distinguish inflammatory bowel diseases. *Nat. Commun.* *10*, 2686.
- 1060 Sallusto, F., and Lanzavecchia, A. (1994). Efficient presentation of soluble antigen by cultured  
1061 human dendritic cells is maintained by granulocyte/macrophage colony-stimulating factor plus  
1062 interleukin 4 and downregulated by tumor necrosis factor alpha. *J. Exp. Med.* *179*, 1109–1118.
- 1063 Satpathy, A.T., Kc, W., Albring, J.C., Edelson, B.T., Kretzer, N.M., Bhattacharya, D., Murphy,  
1064 T.L., and Murphy, K.M. (2012). Zbtb46 expression distinguishes classical dendritic cells and  
1065 their committed progenitors from other immune lineages. *J. Exp. Med.* *209*, 1135–1152.
- 1066 De Schepper, S., Verheijden, S., Aguilera-Lizarraga, J., Viola, M.F., Boesmans, W.,  
1067 Stakenborg, N., Voytyuk, I., Smidt, I., Boeckx, B., Dierckx de Casterlé, I., et al. (2018). Self-  
1068 Maintaining Gut Macrophages Are Essential for Intestinal Homeostasis. *Cell* *175*, 400-415.e13.
- 1069 Schleier, L., Wiendl, M., Heidbreder, K., Binder, M.T., Atreya, R., Rath, T., Becker, E., Schulz-  
1070 Kuhnt, A., Stahl, A., Schulze, L. Lou, et al. (2020). Non-classical monocyte homing to the gut via  
1071  $\alpha 4\beta 7$  integrin mediates macrophage-dependent intestinal wound healing. *Gut* *69*, 252–263.
- 1072 Schlitzer, A., McGovern, N., and Ginhoux, F. (2015). Dendritic cells and monocyte-derived cells:  
1073 Two complementary and integrated functional systems. *Semin. Cell Dev. Biol.* *41*, 9–22.
- 1074 Schridde, A., Bain, C.C., Mayer, J.U., Montgomery, J., Pollet, E., Denecke, B., Milling, S.W.F.,  
1075 Jenkins, S.J., Dalod, M., Henri, S., et al. (2017). Tissue-specific differentiation of colonic  
1076 macrophages requires TGF $\beta$  receptor-mediated signaling. *Mucosal Immunol.* 1–13.
- 1077 Schubert, M., Klinger, B., Klünemann, M., Sieber, A., Uhlitz, F., Sauer, S., Garnett, M.J.,  
1078 Blüthgen, N., and Saez-Rodriguez, J. (2018). Perturbation-response genes reveal signaling  
1079 footprints in cancer gene expression. *Nat. Commun.* *9*, 20.
- 1080 See, P., Dutertre, C.-A., Chen, J., Günther, P., McGovern, N., Irac, S.E., Gunawan, M., Beyer,  
1081 M., Händler, K., Duan, K., et al. (2017). Mapping the human DC lineage through the integration  
1082 of high-dimensional techniques. *Science* (80-. ). *356*, eaag3009.
- 1083 Senda, T., Dogra, P., Granot, T., Furuhashi, K., Snyder, M.E., Carpenter, D.J., Szabo, P.A.,  
1084 Thapa, P., Miron, M., and Farber, D.L. (2019). Microanatomical dissection of human intestinal T-  
1085 cell immunity reveals site-specific changes in gut-associated lymphoid tissues over life. *Mucosal*  
1086 *Immunol.* *12*, 378–389.
- 1087 Shaw, T.N., Houston, S.A., Wemyss, K., Bridgeman, H.M., Barbera, T.A., Zangerle-Murray, T.,  
1088 Strangward, P., Ridley, A.J.L., Wang, P., Tamoutounour, S., et al. (2018). Tissue-resident  
1089 macrophages in the intestine are long lived and defined by Tim-4 and CD4 expression. *J. Exp.*  
1090 *Med.* *215*, 1507–1518.
- 1091 Silva, H.M., Kitoko, J.Z., and Queiroz, C.P. (2021). c-MAF dependent perivascular  
1092 macrophages regulate diet induced metabolic syndrome. Preprint.

- 1093 Smillie, C.S., Biton, M., Ordovas-Montanes, J., Sullivan, K.M., Burgin, G., Graham, D.B., Herbst,  
1094 R.H., Rogel, N., Slyper, M., Waldman, J., et al. (2019). Intra- and Inter-cellular Rewiring of the  
1095 Human Colon during Ulcerative Colitis. *Cell* 178, 714-730.e22.
- 1096 Spencer, J., Siu, J.H.Y., and Montorsi, L. (2019). Human intestinal lymphoid tissue in time and  
1097 space. *Mucosal Immunol.* 12, 296–298.
- 1098 Stoeckius, M., Hafemeister, C., Stephenson, W., Houck-Loomis, B., Chattopadhyay, P.K.,  
1099 Swerdlow, H., Satija, R., and Smibert, P. (2017). Simultaneous epitope and transcriptome  
1100 measurement in single cells. *Nat. Methods.*
- 1101 Stuart, T., Butler, A., Hoffman, P., Hafemeister, C., Papalexi, E., Mauck, W.M., Hao, Y.,  
1102 Stoeckius, M., Smibert, P., and Satija, R. (2019). Comprehensive Integration of Single-Cell  
1103 Data. *Cell* 177, 1888-1902.e21.
- 1104 T’Jonck, W., Williams, M., and Bonnardel, J. (2018). Niche signals and transcription factors  
1105 involved in tissue-resident macrophage development. *Cell. Immunol.* 330, 43–53.
- 1106 Tamoutounour, S., Henri, S., Lelouard, H., de Bovis, B., de Haar, C., van der Woude, C.J.,  
1107 Woltman, A.M., Reyat, Y., Bonnet, D., Sichien, D., et al. (2012). CD64 distinguishes  
1108 macrophages from dendritic cells in the gut and reveals the Th1-inducing role of mesenteric  
1109 lymph node macrophages during colitis. *Eur. J. Immunol.* 42, 3150–3166.
- 1110 Tang-Huau, T.L., and Segura, E. (2019). Human in vivo-differentiated monocyte-derived  
1111 dendritic cells. *Semin. Cell Dev. Biol.* 86, 44–49.
- 1112 Tang-Huau, T.-L., Gueguen, P., Goudot, C., Durand, M., Bohec, M., Baulande, S., Pasquier, B.,  
1113 Amigorena, S., and Segura, E. (2018). Human in vivo-generated monocyte-derived dendritic  
1114 cells and macrophages cross-present antigens through a vacuolar pathway. *Nat. Commun.* 9,  
1115 2570.
- 1116 Thorén, L.A., Liuba, K., Bryder, D., Nygren, J.M., Jensen, C.T., Qian, H., Antonchuk, J., and  
1117 Jacobsen, S.-E.W. (2008). Kit Regulates Maintenance of Quiescent Hematopoietic Stem Cells.  
1118 *J. Immunol.*
- 1119 Travis, M.A., Reizis, B., Melton, A.C., Masteller, E., Tang, Q., Proctor, J.M., Wang, Y.,  
1120 Bernstein, X., Huang, X., Reichardt, L.F., et al. (2007). Loss of integrin alpha(v)beta8 on  
1121 dendritic cells causes autoimmunity and colitis in mice. *Nature* 449, 361–365.
- 1122 Varol, C., Vallon-Eberhard, A., Elinav, E., Aychek, T., Shapira, Y., Luche, H., Fehling, H.J.,  
1123 Hardt, W.-D., Shakhar, G., and Jung, S. (2009). Intestinal lamina propria dendritic cell subsets  
1124 have different origin and functions. *Immunity* 31, 502–512.
- 1125 Villablanca, E.J., De Calisto, J., Paredes, P.T., Cassani, B., Nguyen, D.D., Gabrielsson, S., and  
1126 Mora, J.R. (2014). B7 Integrins Are Required To Give Rise To Intestinal Mononuclear  
1127 Phagocytes With Tolerogenic Potential. *Gut* 63, 1431–1440.
- 1128 Villani, A.-C., Satija, R., Reynolds, G., Sarkizova, S., Shekhar, K., Fletcher, J., Griesbeck, M.,  
1129 Butler, A., Zheng, S., Lazo, S., et al. (2017). Single-cell RNA-seq reveals new types of human  
1130 blood dendritic cells, monocytes, and progenitors. *Science* (80-. ). 356, eaah4573.
- 1131 Villar, J., and Segura, E. (2020). Decoding the Heterogeneity of Human Dendritic Cell Subsets.  
1132 *Trends Immunol.* 41, 1062–1071.
- 1133 Viola, M.F., and Boeckxstaens, G. (2020). Intestinal resident macrophages: Multitaskers of the  
1134 gut. *Neurogastroenterol. Motil.* 32.
- 1135 Watchmaker, P.B., Lahl, K., Lee, M., Baumjohann, D., Morton, J., Kim, S.J., Zeng, R., Dent, A.,  
1136 Ansel, K.M., Diamond, B., et al. (2014). Comparative transcriptional and functional profiling  
1137 defines conserved programs of intestinal DC differentiation in humans and mice. *Nat. Immunol.*  
1138 15, 98–108.
- 1139 Worbs, T., Bode, U., Yan, S., Hoffmann, M.W., Hintzen, G., Bernhardt, G., Förster, R., and  
1140 Pabst, O. (2006). Oral tolerance originates in the intestinal immune system and relies on  
1141 antigen carriage by dendritic cells. *J. Exp. Med.* 203, 519–527.
- 1142 Yin, X., Yu, H., Jin, X., Li, J., Guo, H., Shi, Q., Yin, Z., Xu, Y., Wang, X., Liu, R., et al. (2017).



1143 Human Blood CD1c + Dendritic Cells Encompass CD5 high and CD5 low Subsets That Differ  
1144 Significantly in Phenotype, Gene Expression, and Functions. *J. Immunol.* 198, 1553–1564.  
1145 Zheng, G.X.Y., Terry, J.M., Belgrader, P., Ryvkin, P., Bent, Z.W., Wilson, R., Ziraldo, S.B.,  
1146 Wheeler, T.D., McDermott, G.P., Zhu, J., et al. (2017). Massively parallel digital transcriptional  
1147 profiling of single cells. *Nat. Commun.* 8, 14049.  
1148  
1149



1150

**Fig 1 – Untangling intestinal monocytes and macrophages from transcriptionally similar dendritic cells**

A-C) scRNAseq analysis of 28,758 combined ileal and colonic LP cells, identified as MNP clusters by high average expression of MHCII genes. n = 6 colonic and 4 paired ileal CRC patient samples.

A) scRNAseq experimental outline

B) UMAP of HLA-DR<sup>+</sup> cell clusters with known cell identities. Dashed line encompasses MNP subsets which are not readily identifiable as pDC, cDC1, or non-classical monocytes. Coloured by Louvain clustering.

C) UMAP of normalized gene co-expression of CD1C and CD14

D) Representative flow cytometry gating strategy to identify CD1C<sup>+</sup>/CD14<sup>+</sup> MNP in colon LP

E-G) scRNAseq data of 26,578 combined ileal and colonic LP cells identified by expression of CD1C and/or CD14. n = 6 colonic and 4 paired ileal CRC patient samples

E) Curated heatmap of re-clustered CD1C<sup>+</sup>/CD14<sup>+</sup> cells showing expression of macrophage/DC signature genes averaged per cluster. Showing scaled gene expression: below mean = blue, above mean = red.

F) UMAP of CD1C<sup>+</sup>/CD14<sup>+</sup> cells reclustered at high resolution from clusters within dotted line in Fig. 1C. Dashed line represents major division between clusters identified as Mono/Mac (top) and cDC2/3 (bottom)

G) PC1 and PC2 from pseudo-bulk based PCA of CD1C<sup>+</sup>/CD14<sup>+</sup> cells using signature gene lists from blood cDC2, classical blood monocytes, and monocyte-derived macrophages

1151

1152


1153

1154

1155

1156

1157



1158

**Fig S1 – Initial characterisation of cells in scRNAseq**

A-B) scRNAseq data of 42,506 combined ileal and colonic LP cells, digested and enriched for HLA-DR<sup>+</sup> cells by MACS separation and FACS sorting. n = 6 colonic and 4 paired ileal CRC patients.

A) Signature genes for non-MNP cells in dataset, including T cells, B cells, endothelia, mast cells, stroma, and glia. Showing normalized gene expression.

B) Normalized *HLA-DQA1* expression

C) scRNAseq data of 28,758 computationally isolated and re-clustered MNP from combined ileal and colonic LP cells, showing normalized gene expression of signature genes for pDC, cDC1, and non-classical monocytes.


1159

1160

1161

1162

1163



1164

**Fig 2 – Single-cell characterisation of human intestinal cDC2 and cDC3**

A-D) Single-cell sequencing data of combined colon and ileum LP. Cells identified as transcriptionally cDC2-like were bioinformatically isolated and reclustered.

A) UMAP plot of isolated cDC2-like cells identified in Fig. 1. Coloured by Louvain reclustering at resolution 0.2

B) UMAP plots of cDC2 (top row) and DC3 (bottom row) normalized gene expression of signature genes

C) Curated heatmap of cDC2 and cDC3 DEG. Showing scaled gene expression: below mean = blue, above mean = red.

D) cDC2 vs. cDC3 DEG with proposed immunological functions. Showing scaled gene expression: below mean = blue, above mean = red.


E-F) Surface marker expression of DC2-like clusters analysed by CITE-seq.

E) DSB normalized surface protein expression of selected markers using CITE-seq. n = 3 CRC patients, with 3x colon LP and 1x SI LP, combined.

F) DSB normalized surface protein expression of CD103 vs. CD207 and CD103 vs. CD11a using CITE-seq. n = 3 CRC patients, with 3x colon LP and 1x SI LP, combined.

1165

1166



1167

**Fig S2 - Single-cell and CITEseq Characterisation of cDC2/3**

A) Heatmap of genes identified as DC2 and DC3 signature genes from a peripheral blood dataset, in intestinal cDC2/3 clusters Y1-Y6. n = 6 colon and 4 ileal LP from CRC patients, combined. Showing scaled gene expression: below mean = blue, above mean = red.

B) Expression of *CXCL9* and *CXCL10* on reclustered cDC2/3 cells

C) Heatmap of top 10 DEG for cDC2/3 clusters, using scRNAseq. n = 6 colon and 4 ileal LP from CRC patients, combined. Showing scaled gene expression: below mean = blue, above mean = red.


D) 282-antibody screen (Legendscreen) showing all antibodies with bimodal expression on digested colon LP CD1c+ MNP. Best plots shown of n = 1 or 2 patients analysed per antibody.

E) Violin plots of selected DSB normalized surface marker expression on cDC2/3 clusters using CITE-seq. n = 3 colon LP and 1 ileal LP from 3 CRC patients, combined.

F) DSB normalized cite-seq expression of CD103 vs CD207 and CD103 vs CD11a, for clusters Y3 and Y4

Related to Figure 2

1168



**Fig 3 - cDC development in the human gut**

A-D) Flattened 3D tspace UMAPs (tUMAP) (calculated with pearson on tspace PC (tPC) 1-15 and metric set to pearson) of combined cDC1, cDC2 and cDC3 scRNAseq data

A) cDC1 and Y clusters from Fig. 2, overlaid on tUMAP showing location of cDC1 (grey), cDC2 (Y2, yellow), and cDC3 (Y5, blue and Y6, pink)

B) Cell cycle module score calculated using averaged expression of cell-cycle-associated genes *KIAA0101*, *TUBA1B*, *MKI67*, *HIST1H4C*, *TUBB*, *UBE2C*, *STMN1*, and *H2AFZ*.

C) New cDC clustering with mature cDC clusters from Fig S3A compressed together. Coloured by Louvain clustering, base tPC 1-15.

D) Normalized expression of signature genes for cDC1 (*CLEC9A*), cDC2 (*IRF4*), cDC3 (*C1QA*)


E) Curated heatmap showing of genes associated with proliferation and cDC1, cDC2, or cDC3 signatures. Scaled gene expression: below mean = blue, above mean = red.

F) RNA velocities represented by arrows, calculated with Velocityto package on flattened 3D tUMAP.

G) Pseudotime score calculated as means of trajectories for each cDC cluster, starting in cluster D7, based on tSpace outputs.

1169

1170



1171

**Fig S3 – cDC characterisation**

A) Flattened 3D tspace UMAP (tUMAP) plot of 42 clusters created from combined cDC1, cDC2, cDC3


B) 'Stemness' module score for cDC clusters composed of 20 genes (*BUB1*, *CND2*, *CDC6*, *CDT1*, *CKS2*, *COL18A1*, *CSRP2*, *DTYMK*, *HELLS*, *KPNA2*, *MCM2*, *MCM4*, *MCM5*, *NAP1L1*, *PCNA*, *RRM2*, *SHROOM3*, *SMO*, *TOP2A*, *TTK*) previously identified as forming a general 'stemness' signature

C) RNA velocities represented by arrows analysis for split ileum (n=4) and colon (n=6) overlaid on embeddings of 3D tUMAP.

Related to figure 3

1172

1173



**Fig 4 - Characterisation of human intestinal LP monocyte/macrophage populations**

A-H) tSpace analysis on computationally isolated scRNA-seq data of ileal and colonic LP cells previously identified as belonging to the monocyte-macrophage lineage.

A) tUMAP (with Seurat function) and Louvain clustering (resolution = 0.55) based tPC 1-10 of cells which were identified as Mono/Mac in Fig. 1.

B) Violin plots of normalized gene expression on Mono/Mac trajectory clusters M1-M11. DEG shown are associated with monocyte-macrophage differentiation.

C) Heatmap of select scaled gene expression by Mono/Mac trajectory clusters: below mean = blue, above mean = red.

D) Pseudotime of Mono/Mac clusters calculated from tSpace output with as means of trajectories with starting point in M1.

E) Analysis of response pathway activity in Mono/Mac trajectory clusters M1-M11 using the PROGENy package.

F-J) Violin plots of normalized gene expression by Mono/Mac trajectory clusters. DEG shown are associated with F) pro-inflammatory cytokine secretion, G) response to stimuli, H) efferocytosis, I) CD169+ perivascular macrophages, and J) self-maintaining/wound healing macrophages.


K) DSB normalized expression of surface markers on combined ileal and colonic LP Mono/Mac trajectory clusters using cite-seq, after exclusion of the the small proliferating cluster M11

1174

1175

48





1176

**Fig S4 - Monocyte - macrophage development analysis**

A) Transcription factor activity inferred from target gene expression in Mono/Mac trajectory clusters M1-M10, using the DoRothEA package.

B) Representative staining of all antibodies with bimodal expression on CD14<sup>+</sup> MNP in 361-antibody screen (Legendscreen). Samples taken from digested colonic LP tissue from CRC patients. n= 1-2 patients tested per antibody. Gated on viable CD45<sup>+</sup> HLADR<sup>+</sup> lin<sup>-</sup> cells. Grey line = FMO, red line= specific antibody stain.


C) Representative surface marker expression of colonic LP Mono/Mac subsets using flow cytometry. Gated on viable CD45<sup>+</sup> HLADR<sup>+</sup> lin<sup>-</sup> cells.

D) Gating strategy to identify CD206<sup>-</sup> CD11a<sup>-</sup> macrophages within the CD14<sup>+</sup> CD55<sup>+</sup> gate. Samples concatenated from digested ileal and colonic LP tissue taken from 10 CRC patients.

E) Mono/Mac subset frequencies in ileal IBD and non-IBD biopsies. Samples were taken during IBD surveillance endoscopy and tissue inflammation was scored at the time of the procedure by the clinician. n = 5-13 samples, some samples with different inflammatory scores were taken from the same patient

Related to figure 4

1177



1178

**Fig 5 - Flow cytometry analysis of MNP subsets**

A-E) Flow cytometry analysis of digested tissue taken from unaffected colonic and ileal LP of colorectal cancer patients. n = 10 paired ileal and colonic samples.

A) Gating strategy distinguishing CD1c<sup>+</sup> CD103<sup>+</sup> CD11a<sup>-</sup> cDC2 from CD1c<sup>+</sup> CD103<sup>+</sup> CD11a<sup>+</sup> cDC3 in ileum and colon using either CD103 vs. CD207 or CD103 vs. CD11a, gating on total viable CD45<sup>+</sup> MNP

B) CD11a<sup>-</sup> CD103<sup>+</sup> cDC2 and CD11a<sup>+</sup> CD103<sup>-</sup> cDC3 frequency of total CD14<sup>-</sup> CD1c<sup>+</sup> MNP in ileal and colonic LP. n = 9 CRC patients

C) Representative histograms of CLEC12A and CD1a expression on CD14<sup>+</sup> CD55<sup>+</sup> CD206<sup>-</sup> monocytes, CD1c<sup>+</sup> CD103<sup>+</sup> CD11a<sup>-</sup> cDC2, and CD1c<sup>+</sup> CD103<sup>+</sup> CD11a<sup>+</sup> cDC3 from colon resection

D) Gating strategy to identify monocytes, monocyte-derived early and late intermediates, and two subsets of macrophage

E) Analysis of monocytes and monocyte-derived MNP subsets as a proportion of total CD14<sup>+</sup> cells in colonic and ileal LP

F-J) Flow cytometry analysis of digested tissue taken from colonic biopsies. Extent of IBD inflammation was scored at the time of biopsy by the clinician as quiescent, mild, or moderate. n = 5-13 samples, some samples with different inflammatory scores were taken from the same patient.


F) CD11a<sup>-</sup> CD103<sup>+</sup> cDC2 and CD11a<sup>+</sup> CD103<sup>-</sup> cDC3, as proportion of CD14<sup>-</sup> CD1c<sup>+</sup> MNP, from colonic biopsies. n = 6-10 biopsies from sites of quiescent, mild, or moderate IBD inflammation, or from non-IBD controls. Statistical significance was determined using 2-way ANOVA with Dunnett's multiple comparisons, \*\*p<0.01

G) Representative flow cytometry plots of CD1c vs CD14 stains of UC patient colon LP MNP, with or without vedolizumab treatment

H) CD1c<sup>+</sup> MNP as proportion of total MNP from IBD biopsies, with or without vedolizumab treatment. n = 3-11 biopsies from sites of quiescent IBD inflammation. Statistical significance was determined using Student's T test, \*\*p<0.01

I) CD11a<sup>-</sup> CD103<sup>+</sup> cDC2 and CD11a<sup>+</sup> CD103<sup>-</sup> cDC3 MNP, as proportion of total MNP from IBD biopsies, with or without vedolizumab treatment. n = 2-9 biopsies from sites of quiescent, mild, or moderate IBD inflammation

J) Mono/Mac subsets as proportion of CD14<sup>+</sup> CD1c<sup>lo</sup> MNP, from colonic biopsies. n = 6-14 biopsies from sites of quiescent, mild, or moderate IBD inflammation, or from non-IBD controls. Some points represent single patients with samples taken from multiple sites with different levels of inflammation. Statistical significance was determined using 2-way ANOVA with Dunnett's multiple comparisons, \*p<0.05, \*\*p<0.01 \*\*\*p<0.001



1180

**Fig S5 - Flow cytometry analysis of MNP subsets**

A) Flow cytometry analysis of CD206<sup>+</sup> macrophages from 10 concatenated ileal and colonic resection samples. Gated on CD14<sup>+</sup> CD55<sup>+</sup> MNP

B) CD11a<sup>-</sup> CD103<sup>+</sup> cDC2 and CD11a<sup>+</sup> CD103<sup>-</sup> cDC3, as proportion of CD1c<sup>+</sup> MNP, in ileal biopsies. n = 3 to 4 patients from sites of quiescent, mild/moderate IBD inflammation, or from non-IBD controls. Some points represent single patients with samples taken from multiple sites with different levels of inflammation.

C) CD11a<sup>-</sup> CD103<sup>+</sup> cDC2 and CD11a<sup>+</sup> CD103<sup>-</sup> cDC3, as proportion of HLADR<sup>+</sup> lineage<sup>-</sup> MNP, in colonic biopsies. n = 5 to 10 patients, some points represent single patients with samples taken from multiple sites with different levels of inflammation. Lines represent range of data, boxes represent 25th to 75th percentile intersected by median.

D) CD14<sup>+</sup> cells (monocytes/macrophages) as proportion of total HLADR<sup>+</sup> lineage<sup>-</sup> MNP from IBD biopsies, with or without vedolizumab treatment. Biopsies taken from 5 different sites from 3 vedolizumab-treated patients. Lines represent median ± SD.

E) Mono/Mac subsets as proportion of CD14<sup>+</sup> CD1c<sup>+</sup> MNP, from ileal biopsies. n = 3-6 biopsies from sites of quiescent, mild/moderate IBD inflammation, or from non-IBD controls. Some points represent single patients with samples taken from multiple sites with different levels of inflammation.

Related to figure 5

1181

1182

1183